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1. INTRODUCTION 
1.1. Overview on the Development and Progression of   
Atherosclerotic Lesions 
 
Atherosclerosis is a major cause of morbidity and mortality in developed 
countries and is the underlying basis of most cases of myocardial infarction, stroke 
and peripheral artery disease.  
High plasma concentrations of cholesterol, in particular those of low-
density lipoprotein (LDL) cholesterol, are one of the principal risk factors for 
atherosclerosis, and treatment of hyperlipidemia reduces the risk for 
cardiovascular disease. 1 Accumulation of lipids within the artery wall is a conditio 
sine qua non for the development of atherosclerotic lesions, followed by the 
proliferation of vascular smooth muscle cells and production of extracellular matrix 
leading to a progressive narrowing of the vessel lumen. Therefore, the process of 
atherogenesis has previously been considered to be mainly a disorder of lipid 
metabolism and a lipid deposition disease in the vessel wall.  
Recent developments in vascular biology, however, have indicated that 
atherosclerosis is much more than that. Nowadays atherosclerosis is considered a 
chronic inflammatory disease. Inflammatory processes initiate the formation of 
early lesions, support the development into more complex lesions and even 
participate in acute events, like plaque rupture leading to the above mentioned 
clinical syndromes. 2 
The earliest changes that precede the formation of atherosclerotic lesions 
take place in the endothelium (Figure 1). These changes include increased 
endothelial permeability to lipoproteins and other plasma constituents, the 
upregulation of endothelial adhesion molecules, which include E-selectin, P-
selectin, intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion 
molecule 1 (VCAM-1), the migration of leukocytes into the artery wall, which is 
mediated by oxidized LDL, monocyte chemotactic protein 1 (MCP-1), interleukin-8 
(IL-8), platelet-derived growth factor, macrophage colony-stimulating factor, and 
osteopontin. 
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Figure 1. The 7 stages of the development of a atherosclerotic plaque. First LDL moves 
into the subendothelium and is oxidized by macrophages and smooth muscle cells (SMCs; 1and 
2). Release of growth factors and cytokines attracts additional monocytes (3 and 4). Foam cell 
accumulation and SMC proliferation result in growth of the plaque (6, 7, and 8). 3 
 
Following activation of the endothelium by atherosclerotic risk factors, 
monocytes are recruited into the subendothelial space where they differentiate 
into macrophages. These macrophages endocytose modified forms of low density 
lipoproteins (LDL) via scavenger receptors to form foam cells, the hallmark of fatty 
streak lesions. These lesions develop into fibro-fatty plaques, which contain large 
numbers of macrophages and some CD4+ T cells, and show evidence of smooth 
muscle migration and proliferation. In human arteries, these fibro-fatty plaques 
may develop into complex atherosclerotic lesions that are liable to rupture, or may 
regress when atherosclerotic risk factors are treated. 2 
As fatty streaks progress to intermediate and advanced lesions, they tend 
to form a fibrous cap that walls off the lesion from the lumen. This represents a 
type of healing or fibrous response to the injury. The fibrous cap covers a mixture 
of leukocytes, lipid, and debris, which may form a necrotic core. These lesions 
expand at their shoulders by means of continued leukocyte adhesion and entry 
caused by the same factors. The principal factors associated with macrophage 
accumulation include macrophage colony-stimulating factor, MCP-1, and oxidized 
LDL. The necrotic core represents the results of apoptosis and necrosis, increased 
proteolytic activity, and lipid accumulation. The fibrous cap forms as a result of 
increased activity of platelet-derived growth factor, transforming growth factor β 
(TGF-β), interleukin-1 (IL-1), tumor necrosis factor α (TNF-α), and osteopontin and 
of decreased connective-tissue degradation. 
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Recently, pathologists have advanced the idea of stable and unstable (or 
vulnerable) atherosclerotic plaques. 4 Stable plaques are characterized by a thick 
fibrous cap overlying a plaque that does not contain a cholesterol-rich necrotic 
core. By contrast, unstable plaques have a thin fibrous cap, contain a higher ratio 
of macrophages to smooth muscle cells, and have a lipid-filled necrotic core. 
Unstable plaques are more likely to rupture, which exposes the thrombogenic core 
of the lesion to arterial blood. This leads to platelet aggregation and the formation 
of an arterial thrombus attached to the vessel wall. Thrombus material can break 
away from the wall and be transported to a distant site (embolism), where it may 
lead to blockage of smaller arteries. The clinical consequences of arterial 
thrombosis are heart attacks and strokes. Indeed, the majority (~60%) of arterial 
thrombosis is associated with ruptured atherosclerotic plaques. 4 
Another commonly observed feature of atherosclerotic plaques is 
endothelial cell denudation (plaque erosion) and other changes in the endothelial 
cells that predispose to arterial thrombosis and its clinical sequelae.  
Rupture of the fibrous cap or ulceration of the fibrous plaque can rapidly 
lead to thrombosis and usually occurs at sites of thinning of the fibrous cap that 
covers the advanced lesion. Thinning of the fibrous cap is apparently due to the 
continuing influx and activation of macrophages, which release matrix 
metalloproteinases and other proteolytic enzymes at these sites. These enzymes 
cause degradation of the matrix, which can lead to hemorrhage from the vasa 
vasorum or from the lumen of the artery and can result in thrombus formation and 
occlusion of the artery.  
 
1.2. Endothelial Dysfunction as Primary Step in Ath erosclerosis 
 
The endothelium exerts fundamental control over vascular function, and 
injury to the endothelium followed by dysfunction is an early key event preceding 
manifestation of vessel pathology.  
Endothelial cells form a monolayer that lines the entire vascular system. 
The structural and functional integrity of the endothelium is a fundamental 
requirement for maintenance of vessel wall homeostasis and circulatory function. 
As a semipermeable membrane, endothelium controls the transfer of small and 
large molecules into the arterial wall and through the walls of capillaries and 
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venules. In addition, endothelial cells secrete mediators and express surface 
molecules that participate to the regulation of vascular tone, inflammation, 
thrombosis and fibrinolysis.  
The key initial event in vascular pathology appears to be damage to the 
endothelial cells of the artery. The imbalance between endothelial substances 
responsible for vasorelaxation and vasoconstriction, between procoagulant and 
anticoagulant factors, between proinflammatory and anti-inflammatory mediators, 
and between inhibitors and promotors of vascular cell growth, is an early and 
persistent vascular abnormality in the evolution of atherothrombotic disease in 
humans. 5 The term endothelial dysfunction is often used to describe several types 
of potentially reversible changes in the functional state of endothelial cells that 
occur as a response to environmental stimuli.  
Two functional alterations of endothelium deserve comment: endothelial 
stimulation and endothelial activation.  
Endothelial stimulation denotes a rapid (within minutes), reversible 
response that is independent of new protein synthesis (endothelial cell 
contraction, expression of adhesive glycoprotein P-selectin).  
Endothelial activation depends on new (or altered) protein synthesis and 
requires longer time (hours or even days) to occur. This response is most 
frequently induced by inflammatory cytokines, which promote new adhesion 
molecule expression on the surface of endothelial cells. In addition, the circulating 
cells can be activated by different stimuli, which induce high levels of adhesion 
molecules on the surface of these cells.  
Adhesion molecules expressed on the cellular surface play vital roles in 
numerous cellular processes. Some of these include: cell growth, differentiation, 
embryogenesis, immune cell transmigration and response, and cancer metastasis. 
Adhesion molecules are also capable of transmitting information from the 
extracellular matrix to the cell.  
Cell adhesion molecules (CAMs) are cell surface proteins involved in the 
binding of cells, usually leukocytes, to each other, to endothelial cells, or to 
extracellular matrix. There are four major families of cell adhesion molecules. Most 
of the CAMs characterized so far fall into three general families of proteins: the 
immunoglobulin (Ig) superfamily, the integrin family and the selectin family.  
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The immunoglobulin superfamilies of CAMs are calcium-independent 
transmembrane glycoproteins. Members of the immunoglobulin superfamily 
include the ICAMs, VCAM-1, platelet-endothelial-cell adhesion molecule (PECAM-
1), and neural-cell adhesion molecule (N-CAM). Each immunoglobulin superfamily 
CAM has an extracellular domain, which contains several immunoglobulin-like 
intrachain disulfide-bonded loops with conserved cysteine residues, a 
transmembrane domain, and an intracellular domain that interacts with the 
cytoskeleton. Typically, they bind integrins or other members from immunoglobulin 
superfamily CAMs. Endothelial CAMs play an important role in immune response 
and inflammation. CAMs are critical to numerous cellular processes and 
responses. Additionally, they also play a role in various disease states. 
Transendothelial migration of leukocytes is an example of one of the many roles of 
adhesion molecules.  
The integrin family of CAMs serve as receptors for the ICAMs and 
VCAMs. Two important integrins, Mac-1α and LFA-1β expressed on leukocytes, 
are the ligands for ICAM-1 molecule expressed on endothelial cells. The integrins 
are heterodimeric proteins consisting of an alpha and a beta chain that mediate 
leukocyte adherence to the vascular endothelium or other cell-cell interactions. 
Different sets of integrins are expressed by different populations of leukocytes to 
provide specificity for binding to different types of CAMs expressed along the 
vascular endothelium.  
The selectin family members, P-selectin, L-selectin and E-selectin, are 
involved in the adhesion of leukocytes to activated endothelium. This adhesion is 
initiated by weak interactions that produce a characteristic "rolling" motion of the 
leukocytes on the endothelial surface. P-selectin and L-selectin, acting in concert, 
have been implicated in the mediation of these initial interactions. Stronger 
interactions, probably involving E-selectin, follow the initial interactions, leading 
eventually to extravasation through the blood vessel walls into lymphoid tissues 
and sites of inflammation.  
The leukocyte trafficking consists of four distinct steps. The first is rolling 
of the circulating leukocyte along endothelial cells (i.e., leukocyte rolling on a 
blood vessel wall). This step is selectin-mediated. The second step involves the 
triggering or activation of cell surface adhesion molecules, namely, the integrins. 
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This can be accomplished through contact with specific extracellular matrix 
proteins, inflammatory cytokines, or chemokines. The third step involves firm 
adhesion; the leukocyte firmly attaches to an endothelial cell. This involves arrest 
of the rolling process and spreading over the endothelial surface, typically a vessel 
wall. The integrins and their ligands play crucial roles in this step. The fourth step 
is transmigration of the leukocyte through adjacent endothelial cells in a process 
called diapedesis. This allows the leukocyte to enter the subendothelial space. 
PECAM-1 is a crucial player in this step. Transendothelial migration demonstrates 
cooperativity between leukocyte and endothelial cell adhesion molecules. 
The modulation of these molecules to induce adhesion in inflammation 
can be done using a number of mechanisms, which are dependent on the duration 
of inflammation, the type of inflammatory stimulus and blood flow conditions. 
Redistribution of adhesive molecules to the cell surface (P-selectin), induction of 
adhesion molecules expression on endothelium (ICAM-1, V-CAM-1) and 
increased avidity of binding (ICAM-1 – LFA-1 interaction) are some of these 
mechanisms.  
In summary, different adhesion molecules and chemokines are implicated 
in several stages of the interaction between endothelial cells and circulatory cells. 
The chemotaxis, mediated by chemokines (MCP-1, IL-8), is followed by rolling (P-
selectin), firm adhesion (ICAM-1, VCAM-1) and transmigration (PECAM-1) (Figure 
2).  
 
 
 
 
 
 
 
 
 
Figure 2. Monocyte arrest on the endothelium. Role of adhesion molecules. 
 
All these mediators are upregulated by several transcription factors, 
among which, redox-sensitive NF-κB factor occupies an important position. 
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The presence of atherosclerotic lesions is associated with endothelial 
dysfunction, manifested as impaired endothelium-dependent regulation of 
vascular tone. 6-9 In patients with atherosclerotic risk factors, impaired endothelial 
vasodilator function can be demonstrated early in the process of atherogenesis, 
even prior to the development of frank atherosclerotic lesions. Its extent is related 
to the intensity and duration of risk factor exposure, and treatment of risk factors 
results in reversal or attenuation of endothelial dysfunction. 10-12 These 
observations suggest that the endothelium is both a target and a mediator of 
atherothrombosis.  
Endothelial vasodilator function may therefore serve as an index 
integrating the overall stress imposed by vascular risk factors. Indeed, clinical 
studies have demonstrated that endothelial vasodilator dysfunction is a predictive 
marker for the future development of coronary artery disease, 12 and is associated 
with a worse prognosis in the setting of existing coronary artery disease predicting 
coronary disease progression and cardiovascular event rate. 13,14 These findings 
underscore the central role of the endothelium in vascular function and its 
regulation.  
One marker of endothelial dysfunction is impairment of endothelium-
dependent vasomotor responses, which is indicative of a reduction in the 
bioavailability of the endothelium derived signalling molecule nitric oxide. 15,16 
Nitric oxide is released from endothelial cells in response to increased shear 
stress 17 and certain biochemical stimuli. 18 Nitric oxide may function as an 
endogenous anti-atherogenic molecule by maintaining low arterial tone at rest, 
inhibiting leukocyte–endothelial interactions, attenuating platelet activation, and 
inhibiting smooth muscle cell proliferation. 19 A reduction in nitric oxide synthesis 
and/or activity leading to insufficient biological nitric oxide availability may 
therefore contribute to the initiation and progression of atherosclerosis.  
Decreased nitric oxide bioavailability may reflect an absolute deficit of 
nitric oxide, impaired availability of bioactive nitric oxide or enhanced nitric oxide 
inactivation.  
Decreased nitric oxide synthesis may be due to decreased expression or 
activity of endothelial nitric oxide synthase, alterations of membrane receptors in 
the arterial wall that interact with biochemical or physiological stimuli to induce 
nitric oxide synthesis, decreased availability or affinity of the substrate L-arginine 
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and cofactors, especially tetrahydrobiopterin, for nitric oxide synthase, and 
elevated levels of endogenous inhibitors of nitric oxide synthase.  
Impaired bioavailability and bioactivity of nitric oxide may be due to 
enhanced degradation by increased free radicals and/or oxidation-sensitive 
mechanisms, impaired nitric oxide diffusion from the endothelium to vascular 
smooth muscle cells followed by decreased sensitivity to its vasodilator action, and 
impaired interaction of nitric oxide with guanylate cyclase resulting in decreased 
cyclic GMP production. 19-21  
 
1.3. Hyperhomocysteinemia as a Cardiovascular Risk  
1.3.1. Definition of Hyperhomocysteinemia 
 
In 1969, McCully first described the association of hyperhomocysteinemia 
and the development of premature atherosclerosis and thromboembolism in 
children with rare inborn errors of homocysteine metabolism that presented 
elevated plasma homocysteine levels up to 30 times the normal range. 22,23  
Observations of the natural history of patients with severe 
hyperhomocysteinemia showed that untreated patients suffer one thrombembolic 
event per 25 patient-years 23. A multicenter observational study showed that 
treatment of hyperhomocysteinemia in these patients leads to a significant 
reduction in thromboembolic events compared to untreated patients (relative risk 
0.09; 95% CI 0.036 to 0.228; P < 0.0001). 24  
These data support the hypothesis of a causal relationship between 
severe hyperhomocysteinemia and cardiovascular risk in patients with these rare 
genetic disorders.  
It was Kilmar McCully who first proposed, based on these observations, 
that even mildly elevated plasma homocysteine levels, as found in 5 to 10 percent 
of people in the general population, may play a role in the etiology of vascular 
diseases.  
At present there is no consensus on what levels constitute 
hyperhomocysteinemia. An increased risk for atherosclerotic vascular disease 
seems to be associated with fasting homocysteine levels above 12 µmol/L as 
discussed below. Therefore, it is suggested to refer to fasting plasma 
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homocysteine levels between 12 and 30 µmol/L as mild or – synonymously used – 
moderate hyperhomocysteinemia, to levels between 31 and 100 µmol/L as 
intermediate hyperhomocysteinemia, and to plasma levels > 100 µmol/L as severe 
hyperhomocysteinemia, respectively 5,25,26. 
 
1.3.2. Case-control Studies on Mild Hyperhomocystei nemia and  
Vascular Diseases 
 
A great number of retrospective case-control studies and prospective 
nested case-control studies performed during the last twenty years nearly 
uniformly showed an association between mildly elevated plasma homocysteine 
levels and atherothrombotic vascular diseases indicated by an increased 
prevalence and incidence of coronary artery disease, cerebrovascular disease, 
and peripheral vascular disease.  
Hyperhomocysteinemia persists as a risk factor even after statistical 
adjustment for conventional risk factors, suggesting that homocysteine’s effect on 
cardiovascular disease seems to be independent from other factors.  
Data from a meta-analysis performed by Boushey and colleagues 27 that 
included data from 27 studies published before 1995 indicated that a 5 µmol/L 
increase in plasma homocysteine above median levels of 10 µmol/L is associated 
with a significant and graded increase in the risk of coronary artery disease (odds 
ratio 1.6; 95 % confidence intervall: 1.4 to 1.7), cerebrovascular disease (odds 
ratio 1.5; 1.3 to 1.9), and peripheral vascular disease (odds ratio 6.8; 2.9 to 15.8). 
By comparing elevated homocysteine levels to other established vascular risk 
factors, the authors calculated that a 5 µmol/L increase in plasma homocysteine 
levels is equivalent to a 0.5 mmol/L (20 mg/dL) increase in plasma cholesterol 
levels in increasing the risk for myocardial infarction.  
Data of a recent case-control study conducted in nine European centers 
suggested that the cardiovascular risk associated with elevated homocysteine 
levels detected both under basal conditions (> 12 µmol/L) and after an oral 
methionine challenge (net increase > 27 µmol/L over basal levels or absolute 
increase > 38 µmol/L) is comparable to the risk associated with hyperlipidemia or 
smoking, but somewhat lower than that of hypertension 25.  
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Taking together the above mentioned studies, it has been estimated that 
ten percent of the population’s coronary artery disease risk appears to be 
attributable to plasma homocysteine levels 27. 
 
1.3.3. Prospective Studies on Mild Hyperhomocystein emia and  
Vascular Diseases 
 
Prospective cohort studies, which are providing the most rigorous 
evidence for an association between a potential causal factor and a clinical event, 
however, yielded some inconclusive results in linking homocysteine to vascular 
disease.  
Most of the prospective studies provided evidence for mild 
hyperhomocysteinemia as a risk factor for atherothrombotic vascular disease after 
adjustment for conventional risk factors 28-40, although some studies have not 41-46. 
Possible reasons for these conflicting results may derive from different ethnic 
backgrounds of the study populations, differences in sample size, and most 
importantly, differences in the lifestyle of the specific study’s participants.  
The last point appears to be especially important as a source of potential 
bias owing to multivitamin use by study subjects. For example, the Atherosclerosis 
Risk in Community Trial, the largest prospective trial with a negative outcome, did 
not provide detailed information about vitamin supplementation as a potential 
confounding variable 43-45.  
Nevertheless, the definitive reasons for the variable results are still 
unknown. Several arguments, however, weigh in favor of the positive studies, as 
summarized in Table 1.  
The debate about hyperhomocysteinemia as a cardiovascular risk factor 
will continue, as long as results of large-scaled intervention trials aimed at 
reducing cardiovascular events by homocysteine lowering treatment are still 
pending. Several of these studies are performed at the moment. 
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Table 1. Arguments for mild hyperhomocysteinemia as a cardiovascular risk factor 
(modified with permission from Weiss et al., 47) 
 
 References 
Clear-cut association between hyperhomocysteinemia and 
atherothrombosis in all retrospective case-control studies. 
27 
Correlation of the magnitude of cardiovascular risk with plasma 
homocysteine levels in many studies. 
34,38,39,48,49 
Consistent results of meta-analyses of the retrospective case-
control and of the prospective population based studies favoring 
hyperhomocysteinemia as a vascular risk factor. 
27,39,50-53 
Association between mortality of patients with preexisting 
coronary or peripheral vascular disease and plasma 
homocysteine levels independent of traditional risk factors. 
34,54-59 
Semi-quantitative relation of plasma homocysteine levels with 
the extent of atherosclerosis in coronary, peripheral, and carotid 
arteries.  
53,60-66 
Mildly elevated plasma homocysteine levels induce endothelial 
vascular dysfunction, a key event in the pathogenesis of 
atherothrombosis,  
and lowering of plasma homocysteine levels may have a 
favorable effect on vascular function. 
67-80 
 
 
80-87 
 
 
1.3.4. Causes of Hyperhomocysteinemia and Therapeut ic Options 
 
Homocysteine levels may be determined by nutritional and genetic 
factors, and modified by concomitant disease states and drugs. Plasma 
homocysteine levels are strongly and inversely correlated with plasma levels of 
folate and to a lesser extent with vitamin B6 and vitamin B12 levels 
88,89.  
It has been suggested that inadequate plasma concentrations of one or 
more of these vitamins contribute to approximately two thirds of all cases of 
hyperhomocysteinemia. In accordance with these observations, numerous clinical 
studies, including 12 randomized and placebo controlled intervention studies, 
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have uniformly shown that supplementation with folic acid alone or in combination 
with other B-vitamins is able to effectively lower plasma homocysteine levels, at 
least in patients with normal renal function.  
A recently performed meta-analysis of the published controlled clinical 
trials indicated 90 that folic acid supplementation reduces homocysteine levels by 
25 % (95 % CI: 23 to 28 %) with similar effects in a daily dose range of 0.5 to 5 
mg. An additional reduction in plasma homocysteine is produced by vitamin B12 
(mean dose 0.5 mg), whereas vitamin B6 in a mean dose of 16.5 mg did not have 
any significant effect.  
In addition, elevated plasma homocysteine levels may be increased due 
to genetic defects, as part of the acute phase response, diabetes, chronic renal 
failure, cancer, hypothyroidism, and some drugs (Table 2). 91  
 
Table 2.  Causes of mild hyperhomocysteinemia 
 
Nutritional factors 
Deficiencies of folic acid, vitamin B6 or vitamin B12 
Vegetarian diet 
Chronic alcohol consumption 
 
Genetic defects 
Thermolabile variant of methylenetetrahydrofolate reductase 
Cystathionine β-synthase deficiency 
 
Diseases 
Pernicious anemia 
Renal impairment 
Hypothyroidism 
Diabetes 
Malignancies (acute lymphoblastic leukemia, carcinoma of the breast,   
ovary and pancreas) 
Severe psoriasis 
 
Medications 
Folate antagonists (methotrexat) 
Anticonvulsive drugs (phenytoin, carbamazepine) 
Theophylline 
Nicotinic acid 
Colestipol 
Thiazide diuretics 
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1.4. Chemistry and Metabolism of Homocysteine 
 
Homocysteine occupies a pivotal position in the metabolism of the 
essential sulfur-containing aminoacid, methionine (Figure 3).  
Methionine, in the form of S-adenosyl-methionine, is the major methyl-
group donor in mammals. Homocysteine produced from methionine is metabolized 
either by remethylation to methionine or by transulfuration to cystathionine.  
In all tissues studied so far, remethylation can occur via methionine 
synthase, a vitamin B12 dependent enzyme that uses 5-methyl-tetrahydrofolate (5-
MTHF, a derivative of folic acid) as a methyl donor. In the liver, remethylation may 
be achieved additionally by betaine-homocysteine methyltransferase, the methyl 
donor in this instance being betaine. 
 
 
 
Figure 3.  Scheme of homocysteine metabolism. 
 
Transulfuration of homocysteine is initiated by the enzyme cystathionine β 
synthase (CBS, vitamin B6 or pyridoxine dependent) that forms cystathionine, 
which is finally converted to cysteine. The transsulfuration pathway may end in 
glutathione synthesis, therefore contributing to the maintenance of the cellular 
redox balance. Endothelial cells do not express CBS, therefore they lack the 
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transsulfuration pathway. This may be one reason why they cannot compensate 
homocysteine toxicity by increasing glutathione biosynthesis. 
Remethylation and transsulfuration each account for 50% of 
homocysteine disposal. Remethylation is the major determinant of fasting plasma 
homocysteine levels, whereas impaired transsulfuration increases homocysteine 
levels predominantly when methionine levels are elevated (such as post-
prandially).  
Chemically, methionine contains a sulfide sulfur (R-S-R’), whereas 
homocysteine and cysteine are sulfhydryl compounds (R-SH). Compounds 
containing a free sulfhydryl group are known as “thiols.”  
Other biologically relevant low-molecular-weight thiols are glutathione, 
coenzyme A, and dihydrolipoic acid. Under aerobic conditions (i.e., in the 
presence of molecular oxygen as an electron acceptor) and at physiological pH, 
thiols such as homocysteine, oxidize to form disulfides, according to the general 
reaction:  
2 RSH + O2 ⇔ RSSR + H2O2. 
 
In plasma, this reaction can be catalyzed by transition metals such as 
copper and cobalt (the former present in the circulation associated with albumin 
and ceruloplasmin, the latter with cobalamin).  
Homocysteine can autooxidize readily via general thiol oxidation 
mechanism described above and form homocystine, or oxidize other thiols such 
as cysteine and glutathione to form mixed disulfides, or oxidize free cysteine 
residues on proteins and peptides to form mixed disulfides (Figure 4). 
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Figure 4.  Chemistry of homocysteine and different homocysteine oxidation products. 92 
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1.5. Mechanisms of Homocysteine-Induced Alteration  
of Healthy Endothelium 
 
Experimental data suggests that a key event in the vascular pathology 
associated with hyperhomocysteinemia is endothelial dysfunction and injury 
resulting in decreased vasodilatory capacity, activation of circulating leukocytes 
and platelets, activation of prothrombotic and inhibition of fibrinolytic mechanisms, 
and stimulation of vascular smooth muscle cell proliferation (Figure 5).  
 
 
 
Figure 5. Putative mechanisms and effects of homocysteine-induced endothelial 
dysfunction. Exposure of endothelial cells to homocysteine leads to reduced bioavailability of nitric 
oxide resulting in impaired endothelium-dependent vasodilator function. This may be caused either 
by increased oxidative inactivation of nitric oxide by oxygen-derived free radicals or by increased 
endothelial synthesis of the endogenous nitric oxide synthase inhibitor asymmetric 
dimethylarginine. Decreased bioavailable nitric oxide together with a decrease in the endothelial 
synthesis of prostacyclin promotes platelet activation and aggregation. Elevated homocysteine 
levels induce the expression of several chemokines and adhesion molecules by endothelial cells 
that lead to increased recruitment and adhesion of circulating inflammatory cells. This may be 
caused by decreased bioavailable nitric oxide and/or increased vascular oxidant stress leading to 
increased activation of the redox-sensitive transcription factor NF-κB that may mediate the 
inflammatory response. Homocysteine may further promote thrombosis by activating endothelium-
dependent prothrombotic mechanisms, such as the expression of tissue factor, or the activity of 
factor Va, and by inhibiting antithrombotic and fibrinolytic mechanisms. 5 
 
These cellular events may promote the development of atherosclerotic 
lesions and atherothrombotic clinical manifestations. Increased oxidant stress in 
the vasculature by hyperhomocysteinemia may initiate the pathophysiological 
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changes associated with this cardiovascular risk factor. This may result in the 
depletion of nitic oxide by oxygen-derived free radicals leading to a decrease in 
the bioavailability of this antiatherogenic signalling molecule, as outlined below.  
 
1.5.1. Impaired Endothelium-Dependent Vasodilatatio n as an     
Indicator of Endothelial Dysfunction in Mild Hyperh omocysteinemia 
 
A key regulatory system of the normal activity of the endothelium involves 
nitric oxide synthase (NOS), which synthesizes nitric oxide (NO). This simple 
molecule, besides other effects, acts as an endothelium-derived relaxing factor for 
vascular smooth muscle cells in response to a variety of stimuli. One of the 
important physiologic stimuli is shear stress at the vessel wall, which is increased 
when blood flow increases. The consequent release of NO induces vasodilatation 
and regulates vascular tone. 
Lentz and colleagues used a diet enriched in methionine and depleted in 
folate to increase plasma homocysteine in cynomolgus monkeys. This 
experimental hyperhomocysteinemia impaired endothelium-dependent 
vasodilatation. 93 This observation was confirmed by other studies using rats with 
diet-induced hyperhomocysteinemia, 94,95 or mice with heterozygous disruption of 
the cystathionine β-synthase gene (CBS(-/+)mice), 96-98 or the combination of 
genetic and dietary approaches. 99  
Oral methionine administration (0.1 g/kg body weight) increased plasma 
homocysteine to 25 to 40 µmol/L in young healthy subjects and impaired 
endothelium-dependent vasodilator function, but preserved endothelium-
independent vasodilator responses 67-70,76. The same dysfunction has been 
noticed in patients with chronic mild hyperhomocysteinemia 78,79.  
It seems that homocysteine, and not methionine or vitamin deficiencies, is 
responsible for these adverse vascular effects. Mice with a genetic defect in 
homocysteine transulfuration pathway have mild hyperhomocysteinemia of 1.5 to 
1.8-fold the level in wildtype mice, but have normal plasma methionine levels and 
are provided a chow that yields normal B-vitamin levels. 96-98 Thus, a mild increase 
in homocysteine alone is sufficient to induce endothelial dysfunction. Several 
analyses of different species of homocysteine and their time-dependent 
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concentrations in plasma after oral homocysteine or methionine challenges 
revealed that peak reduction in flow mediated dilation coincided with maximal 
concentrations of reduced homocysteine, but not with free oxidized homocystine, 
protein-bound oxidized homocystine, or related species, 75 suggesting that 
reduced homocysteine is responsible for vascular dysfunction in vivo.  
Decreased accumulation of cyclic guanosine monophosphate, the second 
messenger of nitric oxide mediated vasodilatation, in aortas from mildly 
hyperhomocysteinemic CBS(-/+) mice compared to their wildtype littermates, 96 and 
lower plasma levels of the nitric oxide-derived end-products nitrite and nitrate in 
hyperhomocysteinemic subjects than in healthy controls 80 indicated that the 
effects of homocysteine are presumably due to a decrease in bioavailable 
endogenous nitric oxide. This was also confirmed by the observation that 
homocysteine impairs endothelium dependent vasodilator function induced by 
shear stress, acetylcholine or bradykinin but does not impair endothelium 
independent vasodilatation induced by sodium nitroprusside or nitroglycerin. In 
accordance with these in vivo findings, homocysteine, but not cysteine, has been 
shown to decrease the production and/or bioactivity of nitric oxide and of S-
nitrosothiols by cultured endothelial cells. 97,100,101 
 
1.5.2. Mechanisms of Reduced Nitric Oxide Bioavaila bility in  
Hyperhomocysteinemia 
 
In respiring cells, small amounts of oxygen are reduced to reactive 
oxygen species. These reactive oxygen intermediates, produced in mitochondria, 
peroxisomes, and the cytosol, are scavenged by the cellular defense systems, 
including enzymatic and nonenzymatic antioxidants. A state of moderately 
increased levels of intracellular reactive oxygen species is referred to as oxidative 
stress. Cells respond to this stress by increasing the levels of antioxidants and 
altering the intracellular reduction-oxidation (redox) state.  
Many diseases are linked to damage from reactive oxygen species as a 
result of an imbalance between radical-generating and radical-scavenging 
systems. 
The various risk factors for atherosclerosis, including hyperlipidemia, 
hypertension, diabetes and hyperhomocysteinemia, have in common the 
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generation of intracellular oxidative stress (Figure 6). All these events support the 
development and progression of atherosclerotic lesions and thrombus formation. 
 
 
 
Figure 6.  Roles of reactive oxygen species (ROS) in vascular disease. (MMP-matrix 
metalloproteinase, VSMC-vascular smooth muscle cell) 
 
 
1.5.2.1. Oxidative Inactivation of Nitric Oxide 
 
Nitric oxide (NO), produced by nitric oxide synthases (NOS), is a short-
lived molecule (t1/2=seconds) capable of diffusing across membranes and reacting 
with a variety of targets. Reaction of NO with O2 in aqueous solutions produces 
the relatively unreactive nitrate (NO3
-) and nitrite (NO2
-) ions as products. The 
reaction with other species of O2 generates toxic compounds which disturb the 
equilibrium of the cellular metabolism.  
Depletion of bioavailable nitric oxide by oxidant stress in 
hyperhomocysteinemia has been suggested as one of the mechanisms that 
generate the adverse effects of homocysteine on endothelial function (Figure 7). 
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Figure 7. Putative mechanism of homocysteine-induced increased vascular oxidant 
stress leading to decreased bioavailable nitric oxide. (O2
-.,superoxide anion radical; NO., nitric 
oxide; OONO-,peroxynitrite; H2O2, hydrogen peroxide; Me
x+, metal cation; HO., hydroxyl radical; 
LOOH, lipid peroxide; LOO-, lipid peroxyl radical; LOONO-, lipid peroxynitrite; H2O, water; LOH, 
lipid alcohol.) 5 
 
The reaction between superoxide anion (O2
-) and nitric oxide forms highly 
reactive peroxynitrite (ONOO-), which leads to inactivation of nitric oxide’s 
biological activity. 103 Peroxynitrite has a short half-life, which makes its detection 
difficult in biological systems, 104 but may react with cellular tyrosine residues to 
form nitrosated end-products like 3-nitrotyrosine detected in aortic tissue from 
mildly hyperhomocysteinemic CBS(-/+) mice compared with wildtype mice, 96 and in 
protein lysates from aortic rings cultured in homocysteine containing media. 105 
Elevated levels of superoxide anion were observed in aortic tissue from mildly 
hyperhomocysteinemic mice compared to wildtype mice 96 and in cultured 
endothelial cells incubated with homocysteine. 106 Scavenging of superoxide anion 
by either superoxide dismutase or Tiron reversed endothelial dysfunction in 
hyperhomocysteinemic animal models 96,107 and in isolated aortic rings incubated 
with homocysteine. 106  
Hydrogen peroxide decomposes to the toxic oxygen species hydroxyl 
radical, which can react with all biological macromolecules (lipids, proteins, nucleic 
acids and carbohydrates) causing lipid peroxidation, and to hydroxide anion, 
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which promotes alkaline tissue damage. The initial reaction of peroxidation 
generates a second radical, which in turn can react with a second macromolecule 
to continue the chain reaction. Among the more susceptible targets are 
polyunsaturated fatty acids. Increased plasma levels of the isoprostane F2a-III, an 
end-product of the non-enzymatic peroxidation of arachidonic acid was observed 
in mildly hyperhomocysteinemic CBS(-/+) mice. 96 Increased levels of 
malondialdehyde, conjugated dienes, and oxidized proteins in 
hyperhomocysteinemic patients 108 and the correlation of plasma homocysteine 
with plasma F2 -isoprostanes 109 suggested enhanced in vivo lipid and protein 
oxidation in humans. Oxidant stress induced by hyperhomocysteinemia leads to 
direct oxidation of low-density lipoprotein, 110, and may indirectly contribute to 
oxidative modification of low-density lipoprotein mediated by vascular cells in vitro. 
110 Elevated levels of lipid peroxides lead to an increase in peroxyl radicals that 
can inactivate nitric oxide through the formation of lipid peroxynitrites. An increase 
in the fluorescence of a hydrogen peroxide-sensitive fluorescent probe, 2’,7’-
dichlorofluorescein, was observed in cultured endothelial cells 101,111 and cultured 
vascular smooth muscle cells exposed to homocysteine. 112  
The intracellular redox buffer system has an important role in maintaining 
endothelial function. Reduced glutathione and glutathione disulfide together with 
glutathione reductase and glutathione peroxidase play a central role in the cellular 
defense against oxidant stress. This is confirmed by the findings that nitric oxide 
synthesis is impaired in glutathione-depleted human endothelial cells. Mice 
deficient in cellular glutathione peroxidase have endothelial dysfunction due to 
increased vascular oxidative stress with resulting reduction in the bioavailability of 
nitric oxide. Treatment of hyperhomocysteinemic CBS(-/+) mice with the 
intracellular cysteine donor L-2-oxo-4-thiazolidine carboxylate, an agent that 
increases intracellular levels of reduced glutathione and total thiols and thereby 
shifts the cellular redox state to a more reduced environment, restores endothelial 
function. 98 The involvement of cellular glutathione peroxidase in homocysteine 
induced endothelial dysfunction is demonstrated by the observations that 
overexpression of cellular glutathione peroxidase in hyperhomocysteinemic CBS  
(-/+) mice restores the normal endothelium-dependent vasodilator response, and 
that overexpression of cellular glutathione peroxidase in cultured endothelial cells 
attenuates the homocysteine induced decrease in nitric oxide release from these 
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cells. 97 Improvemnent of the cellular antioxidant capacity by increasing the 
concentration of reduced glutathione or by overexpression of cellular glutathione 
peroxidase compensates for the adverse effects of homocysteine on endothelial 
function. The conclusion that the adverse vascular effects of homocysteine are at 
least partly mediated by oxidative inactivation of nitric oxide is also supported by 
studies in humans demonstrating that pretreatment with antioxidants prevented 
endothelial and platelet dysfunction induced in healthy individuals by an oral 
methionine challenge. 69,71 
Another hypothesis regarding the reduced bioavailability of nitric oxide in 
hyperhomocysteinemia could be the elevation of the plasma concentration of the 
endogenous nitric oxide synthase inhibitor - asymmetric dimethylarginine 113 which 
is generated from the degradation of proteins containing methylated arginine 
residues. 114 Boger and collaborators 115 correlated increased plasma levels of 
asymmetric dimethylarginine with endothelial dysfunction in cynomolgus monkeys 
fed a methionine-rich, folic acid depleted diet free of choline, and in healthy 
humans after an oral methionine challenge. In vitro studies using endothelial cells 
exposed to homocysteine or to methionine, have shown that the concentration of 
asymmetric dimethylarginine in the cell culture medium was increased in a dose- 
and time-dependent manner and associated with reduced nitric oxide synthesis by 
endothelial cells. This was due to a reduction of the activity of dimethylarginine 
dimethylaminohydrolase, the enzyme that degrades asymmetric dimethylarginine 
in hyperhomocysteinemic conditions. This inhibitory effect of homocysteine on this 
enzyme could be caused by direct binding and functional interference of the 
reactive sulfhydryl group of homocysteine with cysteine groups of dimethylarginine 
dimethylaminohydrolase, as it can be prevented by a thiol antioxidant that protects 
sulfhydryl groups and by the reducing agent dithiothreitol, 116 or by increased 
oxidant stress under conditions of elevated homocysteine. 117 These observations 
complement the hypothesis that homocysteine may impair nitric oxide bioactivity 
by oxidative degradation.  
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1.5.2.2. Involvement of Nitric Oxide Synthase in th e Generation 
of Reactive Oxygen Species 
 
Nitric oxide is produced by a group of enzymes called nitric oxide 
synthases (NOS). These enzymes catalyze the production of nitric oxide and L-
citrulline from L-arginine, O2, and NADPH-derived electrons. Mammalian systems 
contain three well-characterized isoforms of the enzyme: neuronal NOS (nNOS, 
also called NOS1), inducible NOS (iNOS or NOS2), and endothelial NOS (eNOS 
or NOS3). The three main isoforms share structural similarities and have nearly 
identical catalytic mechanisms. They all require a number of cofactors and 
functional prosthetic groups for activity including FAD, FMN, heme, calmodulin, 
and tetrahydrobiopterin. The homodimeric form is required for nitric oxide 
production, and the subunits have molecular masses of approximately 160 
(nNOS), 135 (eNOS), and 130 kDa (iNOS).  
Several studies have demonstrated that homocysteine induces increased 
formation of peroxynitrite. Unlike superoxide, peroxynitrite is both able to initiate 
lipid peroxidation 118 and to react with DCF 119. In vitro experiments suggested that 
homocysteine-induced oxidant stress is stereospecific for the naturally occuring L-
isoform, indicating a biochemical rather than chemical basis for the effect. In these 
experiments, increased lipid peroxidation was observed in endothelial cells 
incubated with L-homocysteine, but not with D-homocysteine, as measured by 
total isoprostane F2α-III and TBARs levels in the supernatant of endothelial cell 
cultures. Stereospecificity was also observed for DCF fluorescence in situ, 
indicating a parallel effect on overall reactive oxygen species content. Enhanced 
lipid peroxidation and DCF-fluorescence was not observed with either cysteine or 
glutathione, and was not due to extracellular thiol oxidation, as it could be fully 
replicated with the oxidized disulfide form of homocysteine, L-homocystine. 
Mechanistically, this pro-oxidant effect seems to be dependent upon both 
endothelial nitric oxide synthase and superoxide anion.  
Inhibition of endothelial nitric oxide synthase with L-nitroarginine methyl 
ester (L-NAME) completely blocked the homocysteine-dependent stimulation of 
reactive oxygen species formation as measured by DCF-fluorescence. 
Furthermore, L-NAME completely abrogated the homocysteine-dependent 
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increase in isoprostane F2α-III formation. Transfection of endothelial cells with 
superoxide dismutase cDNA blocked the effect of homocysteine on endothelial 
cell lipid peroxidation, whereas addition of extracellular superoxide dismutase had 
no effect. Importantly, neither the addition of extracellular catalase nor loading 
cells with catalase had any effect on lipid peroxidation. This indicates that 
hydrogen peroxide is not involved in this process. The reactive oxygen species 
produced rather seems to be superoxide anion.  
Although the precise mechanism by which homocysteine may induce 
increased superoxide anion and peroxynitrite formation remains to be elucidated, 
two potential mechanisms include endothelial nitric oxide synthase “uncoupling”, in 
which endothelial nitric oxide synthase (eNOS) is the source of superoxide 
consecutively peroxynitrite; and increased superoxide production from other 
enzymatic sources. In both situations some of the excess superoxide reacts with 
nitric oxide to form peroxynitrite (Figure 8).  
 
 
 
 
 
 
 
 
 
Figure 8.  Hypothetical mechanism of nitric oxide synthase-dependent generation of 
reactive oxygen species in hyperhomocysteinemia. L-homocysteine and L-homocystine, but not 
the respective D-isoforms, increase membrane lipid peroxidation and DCF-fluorescence in cultured 
endothelial cells. This effect is dependent on eNOS and superoxide anion (O2
-), as L-NAME and 
transfection of endothelial cells with superoxide dismutase cDNA, respectively, blocks hcy’s 
effects. Increased O2
- may result from “uncoupling” of eNOS and/or from other enzymatic sources. 
Some of the excess O2
- reacts with nitric oxide (NO) to form peroxynitrite (ONOO-). This reaction 
leads to biological inactivation of NO. Furthermore, ONOO- initiates lipid peroxidation and 
increases DCF-fluorescence. 92 
 
Bioavailability of nitric oxide is determined by the balance between its 
synthesis by eNOS and its inactivation by superoxide anions. The NOS enzymes 
use 5,6,7,8-tetrahydrobiopterin (BH4) as a cofactor for transfer of electrons from a 
heme group within the oxygenase domain to L-arginine to form L-citrulline and NO. 
If either BH4 or L-arginine is absent, the electrons from heme reduce oxygen to 
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form superoxide. This phenomenon called “uncoupling” of eNOS has been also 
observed during intracellular L-arginine deficiency and increased LDL-cholesterol 
concentrations. Topal and colleagues 120 examined the participation of eNOS in 
the homocysteine-induced alterations of NO/O2
- balance in endothelial cells from 
human umbilical cord vein. The inhibitory effect of homocysteine on nitric oxide 
release was associated with increased production of reactive nitrogen and oxygen 
species and was suppressed by the NOS inhibitor L-NAME. L-NAME markedly 
decreased reactive nitrogen and oxygen species formation and the ethidium red 
fluorescence (indicative of superoxide formation) induced by homocysteine. This 
eNOS-dependent O2
- synthesis was associated with reduced intracellular levels of 
both total biopterins and tetrahydrobiopterin and increased release of 7,8-
dihydrobiopterin and biopterin in the extracellular medium. Their results have 
shown that the oxidative stress and inhibition of NO release induced by 
homocysteine depend on eNOS uncoupling due to reduction of intracellular 
tetrahydrobiopterin availability. Therefore, eNOS itself can contribute to 
superoxide anion formation under conditions of elevated homocysteine levels. 
 
1.5.2.3. Elevation of the Oxidation Rate of Homocys teine in  
Hyperhomocysteinemia 
 
Homocysteine, like other thiol-containing amino acids, added to plasma 
undergoes auto-oxidation, which is accompanied by the generation of reactive 
oxygen species, such as hydrogen peroxide or superoxide anion. 110  
An elevation of the oxidation rate of homocysteine and cysteine, 
expressed as a decreased ratio of reduced to total aminothiols in plasma, has 
been shown in experimental hyperhomocysteinemia after a methionine load 121-123 
and in hyperhomocysteinemic patients. 124-127 This notion is supported by the 
observation that 1% or less of total homocysteine species consists of free 
homocysteine in the plasma of healthy humans under physiological conditions, 
whereas 5-15% consist of homocystine, another 5-15% are mixed disulfides 
(cysteine-homocysteine or glutathione-homocysteine), and more than 70% is 
protein-bound 121.  
More recent evidence, however, suggests that oxidized forms of 
homocysteine in plasma arise primarily via disulfide exchange, with only a small 
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fraction resulting from direct homocysteine oxidation 128. Hence, the contribution of 
direct homocysteine oxidation to homocysteine-induced vascular oxidative stress 
may not be as important as enzymatic mechanisms.  
 
1.5.2.4 Inhibition of Cellular Antioxidant Enzymes by Homocysteine 
 
The cellular defense system against reactive oxygen species includes 
several antioxidant enzymes and non-enzymatic antioxidants, such as α-
tocopherol, ascorbic acid, β-carotene, and glutathione.  
Homocysteine has been shown in particular to disrupt the normal function 
of two important cellular antioxidant enzymes, the cellular isoform of glutathione 
peroxidase (GPx-1) and superoxide dismutase. As shown in vitro and in vivo 
studies, homocysteine, but not other low-molecular-weight thiols, decreases both 
the expression and specific activity of GPx-1. 97,98,100,129,130 This key enzyme for 
the cellular defense against oxidant stress uses glutathione to reduce hydrogen 
peroxide and lipid peroxides to their respective alcohols, 131 and may also act as a 
peroxynitrite reductase 132. Transition metal ions such as iron and copper catalyze 
the breakdown of hydrogen peroxide to form hydroxyl radical (•OH), which is 
highly reactive and causes lipid peroxidation, among its numerous effects; and 
hydroxide anion (OH-), which promotes alkaline tissue damage. This process is 
offset in part by catalase and GPx-1-dependent reduction of H2O2 to H2O. 
Elevated levels of lipid peroxides are accompanied by an increase in peroxyl 
radicals, which can inactivate nitric oxide through the formation of lipid 
peroxynitrites 133,134. Thus a deficiency of GPx-1 may lead to a decrease in 
bioavailable nitric oxide via at least two mechanisms, an increase in reactive 
oxygen species and an increase in lipid hydroperoxides.  
Extracellular superoxide dismutase is a secreted glycoprotein with an 
affinity for heparin-like glycosaminoglycans. It is present in the circulation in an 
equilibrium between the glycosaminoglycans on the endothelial surface and the 
plasma phase, and acts as the principal enzymatic scavenger of superoxide in the 
extracellular space. 135,136 The plasma levels of extracellular superoxide dismutase 
correlate positively with plasma homocysteine levels in homocystinuric patients 137 
and in patients with mild hyperhomocysteinemia 138. This effect is caused by 
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decreased binding of extracellular superoxide dismutase to endothelial cell 
surfaces by alterations in endothelial heparan sulfate proteoglycans by 
homocysteine 139. This effect may result in a loss of the ability to protect the 
endothelial surface from oxidative stress, although this hypothesis has not yet 
been definitively proven. 
In summary, experimental data suggest that elevated levels of 
homocysteine lead to increased vascular generation of reactive oxygen species, 
primarily by a mechanism involving nitric oxide synthase, and secondarily due to 
increased homocysteine oxidation. These effects are further amplified by 
alterations in the function of important cellular antioxidant enzymes. The resultant 
vascular oxidant stress may lead to vascular dysfunction. 
 
1.5.3. Recruitment and Adhesion of Circulating Mono nuclear Cells to  
the Endothelium as Marker of Homocysteine-Induced  
Endothelial Dysfunction 
 
In addition to an impairment of endothelium-dependent vascular reactivity, 
homocysteine-induced endothelial dysfunction may be manifest as an activation of 
endothelial cells leading to increased expression of chemokines and adhesion 
molecules resulting in increased recruitment of circulating inflammatory blood cells 
and their increased adhesion at the endothelium. All these events are known to 
play an important role in the pathogenesis of early atherosclerotic lesions and their 
progression.  
Cellular adhesion molecules, particularly members of the selectin family 
and immunoglobulin superfamily, are intimately involved in the recruitment of 
leukocytes to sites of inflammation, including developing atherosclerotic lesions, 
and their role in the pathogenesis of atherosclerosis has now been clearly 
demonstrated. Plasma levels of cellular adhesion molecules have been 
associated with many conventional and emerging cardiovascular risk factors and 
acute coronary events. They have also been proposed to be of potential value in 
the prediction of future cardiovascular risk, and as potential targets for therapeutic 
intervention.  
Incubation of cultured endothelial cells with homocysteine has been 
shown to increase the expression of the chemoattractant proteins MCP-1 and IL-8 
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leading to increased chemotaxis of human peripheral blood monocytes and U937 
cells. 140 Previous works showed that homocysteine increased P-selectin 
expression by activated / dysfunctional endothelial cells and / or platelets in mildly 
hyperhomocyst(e)inemic CBS
(-/+)
 mice determined by ELISA for soluble P-selectin 
and immunostaining of aortic section 98 events which can be avoided by 
antioxidant therapy.  
Induction of hyperhomocyst(e)inemia in apoE-null mice (by a diet 
enriched in methionine but depleted in folate and vitamins B6 and B12) enhanced 
the expression of receptors for advanced glycation end products (RAGE), VCAM-
1, tissue factor (TF) and MMP-9 in the vasculature. This went along with an 
increase in atherosclerotic lesion area and complexity 141, pointing out that 
hyperhomocysteinemia may promote atherosclerotic lesion progression via an 
enhanced vascular inflammatory response. The mechanisms underlying these 
observations are not yet clear.  
Reduced bioavailability of nitric oxide promoting P-selectin expression 98 
and/or activation of the redox sensitive transcription factor NF-κB regulating 
adhesion molecules expression, tissue factor and RAGE expression 141 may be 
involved in the vascular inflammatory response to hyperhomocysteinemia.  
 
1.5.4. Reduced Endothelial Progenitor Cell Recruitm ent and  
Proliferation and Increased Endothelial Cell Apopto sis in  
Hyperhomocysteinemia 
 
Studies from several groups have shown that homocysteine decreases 
the proliferation rate of cultured vascular endothelial cells and induces 
programmed cell death in cultured endothelial cells which might contribute to 
endothelial cell injury in hyperhomocysteinemia. 129,142,143 
Chen and collaborators investigated whether homocysteine has 
influences on endothelial progenitor cells number and activity. 144 Incubation of 
isolated human mononuclear cells with homocysteine decreased the number of 
endothelial progenitor cells in a dose and time dependent way, a maximum effect 
could be observed when incubating with 200 µmol/L for 24 hours. In addition, 
homocysteine dose and time dependently impaired endothelial progenitor cells 
capacity to adhere and to induce vasculogenesis in vitro.  
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Zhang and colleagues 142 showed that homocysteine induced 
programmed cell death in human umbilical vein endothelial cells as measured by 
the TdT-mediated dUTP nick end labeling assay, DNA ladder formation, induction 
of caspase 3-like activity, and cleavage of procaspase 3. Homocysteine-induced 
cell death was specific to homocysteine, was not mediated by oxidative stress, 
and was mimicked by inducers of the unfolded protein response (UPR), a signal 
transduction pathway activated by the accumulation of unfolded proteins in the 
lumen of the endoplasmic reticulum.  
These data are confirmed by another study, which shows that 
homocysteine induces upregulation of Fas in endothelial cells in a dose-
dependent manner. Homocysteine-induced Fas expression was inhibited by the 
treatment with catalase. In addition, homocysteine inhibited expression of the 
caspase-8 inhibitor FLICE-inhibitory protein (FLIP). These data suggest that 
upregulation of Fas expression and downregulation of FLIP may be a mechanism 
through which homocysteine induces endothelial cell apoptosis. 145 
 
1.5.5. Inhibition of Endothelial Cell Thromboresist ance by  
Homocysteine 
 
The mechanisms by which homocysteine may contribute to atherogenesis 
may involve thrombogenic mechanisms: homocysteine increases thromboxane-
mediated platelet aggregation in vitro likely by reducing nitric oxide bioavailability 
146 or by decreasing the biosynthesis of prostacyclin, 147,148; increases tissue factor 
expression 149 and the activation of factor V to factor Va, 150 thus favouring 
thrombin generation through initiation and propagation of the coagulation cascade. 
In addition, homocysteine may inhibit inactivation of factor Va by activated protein 
C through homocysteinylation of the cofactor, and may reduce the binding of 
antithrombin III to the endothelial surface through inhibition of heparan sulphate 
expression. 151 Homocysteine decreases the expression of endogenous 
anticoagulants and inhibits fibrinolysis 152,153. It modulates thrombomodulin 
expression and activity, and thrombomodulin-dependent activation of the 
anticoagulant protein C by thrombin. 154 All these observations suggest that 
hyperhomocysteinemia promotes thrombosis. However, most of the in vitro 
studies mentioned above were performed with homocysteine concentrations 
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above pathophysiologically relevant levels, or were reproduced with cysteine, and, 
thus, could be related to the non-specific reactivity of the sulfhydryl group of 
homocysteine.  
Support of the hypothesis that mild hyperhomocysteinemia induces a 
prothrombotic state in vivo is derived from animal studies and clinical 
observations. Dietary folate deficiency in rats induces platelet hyperreactivity and 
increases macrophage tissue factor activity, effects that correlate with increases in 
homocysteine levels. Plasma homocysteine concentrations induced by methionine 
challenge in rats correlated with platelet aggregation and increased synthesis of 
the proaggregant thromboxane A2. Increased thromboxane A2 synthesis has also 
been documented in homocystinuric patients. 155 In addition, plasma 
homocysteine concentrations were found to correlate with plasma fibrinogen levels 
in mildly hyperhomocysteinemic patients with coronary heart disease, 63 and 
increased levels of von Willebrand factor were found in mildly 
hyperhomocysteinemic patients with premature arterial disease and in healthy 
individuals after methionine challenge. 156 Together with a reduction of the 
antiplatelet effects of nitric oxide by homocysteine, these findings further support 
the view that increased platelet activation and aggregation may be involved in the 
development of thrombosis in hyperhomocysteinemia. 
 
1.6. Influence of Homocysteine on Circulating Monon uclear Cells  
   
In vivo and in vitro studies have shown that homocysteine not only 
influences the endothelium but also the phenotype of circulating mononuclear 
cells. The changes at both levels may contribute to accelerated formation and 
promotion of atherosclerotic lesions. 
Beauchamp et al. 157 have shown that homocysteine increased - in a 
time- and dose-dependent manner - lipoprotein lipase mRNA expression and 
secretion in J774 macrophages, the levels of c-fos mRNA and enhanced nuclear 
protein binding to the AP-1 sequence of the lipoprotein lipase gene promoter. The 
experiments demonstrated that homocysteine-induced lipoprotein lipase mRNA 
expression requires PKC activation. These observations suggest a new 
mechanism by which homocysteine may exert its proatherogenic effects in human 
diabetes. 
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Another set of experiments revealed that VEGF mRNA was upregulated 
by homocysteine in a dose- and time-dependent manner in THP-1 macrophages 
accompanied by an increase in VEGF secretion. Importantly, other sulfur 
compounds, such as methionine and cysteine, showed no effect on VEGF 
expression, indicating that homocysteine specifically induced VEGF. These 
findings suggest that hyperhomocysteinemia could promote the development of 
atherosclerotic lesions through VEGF induction in macrophages. 158 
The induction of oxidant stress in hyperhomocysteinemia was confirmed 
by the finding that human neutrophils exposed to homocysteine released 
superoxide anion to the extracellular medium, and that this effect could be 
inhibited by superoxide dismutase and diphenyleneiodonium (DPI), an inhibitor of 
NADPH oxidase activity. In addition, homocysteine increased intracellular H2O2 
production by neutrophils, enhanced the activation and phosphorylation of 
mitogen-activated protein kinases (MAPKs), specifically p38-MAPK and ERK1/2, 
and increased migration of neutrophils. This is the first evidence that 
homocysteine enhances the oxidative stress of neutrophils, and underscores the 
potential role of phagocytic cells in vascular wall injury through superoxide anion 
release under hyperhomocysteinemic conditions. 159 
In vivo experiments using methionine feeding in C57BL/6 mice resulting in 
hyperhomocysteinemia showed that superoxide anion radical levels in peritoneal 
macrophages and NF-κB binding activities were higher in the methionine group 
than in the control group. These data suggest that hyperhomocysteinemia may 
intensify disturbances in peroxidation and inflammatory mediator activation in 
peritoneal macrophages, which could be a possible mechanism of homocysteine’s 
atherogenic effects. 160 
 
1.6.1. Increased Recruitment and Chemotaxis of Homo cysteine- 
Stimulated Monocytes to Unstimulated Endothelial Ce lls 
 
Homocysteine-mediated leukocyte-endothelial cell interaction is one 
potential mechanism by which hyperhomocysteinemia may lead to the 
development of atherosclerosis due to promotion of vascular inflammation.  
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In vitro studies performed by Koga and collaborators revealed a 
significant increase in monocyte (U937) adhesion to HAEC when only U937 cells 
were treated with homocysteine or when both cell types were treated with 
homocysteine. The process seemed to be mediated by VCAM-1. 161  
Monocyte chemoattractant protein-1 (MCP-1), which is a potent 
chemokine that stimulates the migration of monocytes into the intima of arterial 
walls, seems to be modulated by homocysteine at the expression level. Wang et 
al. 162,163 showed that homocysteine induces monocyte chemoattractant protein-1 
expression in vascular smooth muscle cells and THP-1 macrophages by activating 
NF-kB. The same group has also shown that homocysteine stimulates the 
expression of the MCP-1 receptor (CCR2) in human monocytes, an effect that is 
possibly mediated by oxygen-derived free radicals. 164 
 
1.6.2. Possible Involvement of Inducible Nitric Oxi de Synthase  
Enzyme in Homocysteine-Induced Oxidative Stress in Monocytes 
 
Isolation of iNOS, a 130 kDa cytoplasmatic protein, was first reported in 
macrophages where its activity was found to be inducible in response to stimuli 
such as proinflammatory cytokines or endotoxin. Expression of iNOS has now 
been reported in a large number of cell types, and in most circumstances, the 
enzyme is inducible. The iNOS gene is under transcriptional control although 
activity is also influenced by a variety of other control mechanisms that affect 
mRNA stability, translation and degradation of the protein, and availability of 
substrate and cofactors. iNOS activity is not responsive to changes in intracellular 
Ca2+ levels and thus this isoform is capable of a high output and long-lasting 
release of nitric oxide far exceeding that of the other isoforms. iNOS produces 
physiological concentrations of nitric oxide in the nanomolar range whereas the 
Ca2+-dependent isoforms produce picomolar concentrations of nitric oxide. iNOS, 
like the other two members of NOS family, requires a number of cofactors and 
prosthetic groups for activity including FAD, FMN, heme, calmodulin, and 
tetrahydrobiopterin. 
The iNOS expression in mouse macrophages was shown to be induced 
by activated NF-κB 165,166. The promoter of iNOS contains two consensus 
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sequences for the binding of NF-κB, which mediates LPS-inducibility 165. The 
heterodimer of p65/p50 has been reported as a NF-κB complex responsible for 
LPS-induced iNOS expression.  
 
1.6.3. Activation of NF- κB in Monocytes and Endothelial Cells 
by Oxidant Stress 
 
The transcription factor NF-κB is activated by a variety of stimuli and 
regulates diverse gene expressions and biological responses. The stimuli include 
bacterial endotoxin, lipopolysaccharide (LPS), ionizing radiation, and carcinogens 
that are often associated with inflammatory diseases or tumor development. 
Recent observations support that NF-κB activation also may be important in 
pathogenesis of chronic diseases such as atherosclerosis and diabetes. 167 
Activated NF-κB was found in atherosclerotic lesion 168. Physiological modulation 
and pathological activation of the NF-κB system may contribute to the changes in 
gene expression that occur during atherogenesis. Diverse stimuli activate NF-κB, 
through the phosphorylation and activation of the IκB kinase (IKK) complex. This 
complex consists of IKK-α and IKK-β heterodimers, a number of IKK-γ subunits, 
and possibly other components whose significance is less certain. The activated 
IKK complex specifically phosphorylates IκBs, which are then rapidly 
polyubiquitinated, targeting them for degradation by the proteosome. Following 
release from the inhibitor, NF-κB dimers translocate from the cytoplasm to the 
nucleus, where they bind target genes and stimulate transcription.  
NF-κB activates a variety of target genes relevant to the pathophysiology 
of the vessel wall, including cytokines, chemokines, and leukocyte adhesion 
molecules, as well as genes that regulate cell proliferation and mediate cell 
survival. For example, human monocytic cell (THP-1)-derived macrophages 
incubated with pathophysiologic concentrations of homocysteine were shown to 
have significantly enhanced expression of MCP-1 mRNA (up to 2.6-fold) and 
protein (up to 4.8-fold) due to increased translocation of NF-κB. 163  
NF-κB is one of the transcription factors that may be controlled by the 
redox status of the cell. 169 Indeed, generation of reactive oxygen species may be 
a common step in all of the signalling pathways that lead to IκB degradation and 
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NF-κB nuclear accumulation. Support for this concept comes from a variety of 
studies showing that the diverse agents that can activate NF-κB also elevate 
levels of reactive oxygen species and that chemically distinct antioxidants, as well 
as overexpression of antioxidant enzymes, can inhibit NF-κB activation. 169  
Au-Yeung et. al 188 showed that oxidant stress due to 
hyperhomocysteinemia results in increased activation of the redox-sensitive 
transcription factor NF-κB in endothelial cells. Other studies have revealed that 
pathophysiological levels of homocysteine can alter human monocyte function by 
upregulating MCP-1 and IL-8 expression and secretion via enhanced formation of 
intracellular ROS originated from NAD(P)H oxidase source via calmodulin or 
protein kinase C signaling pathways. Homocysteine-induced ROS generation 
subsequently activates mitogen-activated protein kinase (p38 and ERK1/2) and 
NF-κB in a PPARγ activator–sensitive manner. 170 However, a direct role of 
reactive oxygen species in signalling to NF-κB remains to be proven. 
 
 
 
 
40 
2. HYPOTHESIS OF THE STUDY 
The purpose of this thesis is to show potential mechanisms by which 
pathophysiologically relevant concentrations of homocysteine influence the normal 
interaction between cultured endothelial cells and cultured mononuclear cells, and 
thereby promote vascular inflammation. 
The specific hypotheses for these in vitro experiments can be 
summarized as follows: 
 homocysteine enhances the expression of adhesion molecules on 
endothelial cells and monocytes (i.e. P-selectin, E-selectin, ICAM-1, 
VCAM-1, PECAM-1, TF, RAGE, β-2 integrins) leading to increased 
adhesion of mononuclear cells to the endothelium; 
 these effects are mediated by increased intracellular reactive oxygen 
species and/or a depletion of bioavailable NO and enhanced NF-κB 
activity; 
 only the naturally occurring L-stereoisomer of homocysteine can 
promote the activation of endothelial cells and monocytes. 
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3. MATERIALS AND METHODS 
3.1. Chemicals and Cell Culture Ware 
 
D,L-homocysteine (D,L-hcy) and L-homocysteine thiolactone hydrochloride 
were from Sigma Chemical Co, D-homocysteine thiolactone hydrochloride and L-
cysteine (L-cys) were from Fluka. L-homocysteine thiolactone hydrochloride and D-
homocysteine thiolactone hydrochloride were hydrolyzed to L-homocysteine (L-
hcy) and D-homocysteine (D-hcy), respectively, using the following protocol. 15.36 
mg of the thiolactone were dissolved in 1 mL H2O. After that 1 mL of 0.1 M NaOH 
was added and the solution was incubated 15 minutes at 37°C. The pH was 
adjusted with 1N NaOH to 9. 171,172 Final thiol concentrations were determined 
spectrophotometrically using Ellman’s reagent. D,L-homocysteine and L-cysteine 
were freshly prepared as 100 mmol/L stock solutions in DMEM 2% FBS. 
Recombinant human tumor necrosis factor (TNF-α), Tiron (4,5-dihydroxy-
1,3-benzenedisulfonic acid disodium salt pyrocatechol-3,5-disulfonic acid disodium 
salt), L-sepiapterin (S(-)-2-Amino-7,8-dihydro-6-(2-hydroxy-1-oxopropyl)-4(1H)-
pteridinone), lipopolysaccharides from Escherichia coli O26:B6 were from Sigma 
Chemical Co.  
Monoclonal mouse anti-human antibodies against ICAM-1 (clone 8.4 A6), 
E-selectin (clone1.2 B6) and PECAM-1 (clone JC 70A) and the respective murine 
IgG1 isotype control were from Sigma Chemical Co, monoclonal mouse anti-
human antibody against VCAM-1 (clone 1.4 C3) and rabbit anti-mouse IgG 
antibody coupled with FITC were from DAKO. Monoclonal mouse anti-human 
antibodies against LFA-1β (CD18; clone R3.3), and Mac-1α (CD11b; clone LM2/1) 
were from Bender MedSystems. 
BCECF/AM (2‘,7‘ – bis - (2 - carboxyethyl) – 5 - (6‘) - carboxyfluorescein 
acetoxymethyl ester) prepared as 1 mg/mL stock in dimethylsulfoxide (DMSO) and 
2',7'-dichlorodihydrofluorescein diacetate (DCF-DA) prepared as 100 mmol/L stock 
in DMSO were from Calbiochem. L-012 (8-amino-5-chloro-7-phenylpyridol (3,4-d) 
pyridazine-1,4 (2H,3H) dione) was obtained from Aventis. 
The cell-permeable superoxide dismutase (SOD) mimetic and 
peroxynitrite scavenger MnTBAP (Mn(III)tetrakis (4 - benzoic acid) porphyrin 
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chloride) was from Calbiochem and prepared as 5 mg/mL stock in water. The cell-
permeable SOD mimetic Tiron (4,5-Dihydroxy-1,3-benzenedisulfonic acid 
disodium salt) was purchased from Sigma. 
E3-((4-Methylphenyl)sulfonyl)-2-propenenitrile (BAY 11-7082 10 µmol/L in 
DMSO; Sigma Chemical Co.) was used to decrease nuclear translocation of NF-
κB. BAY11-7082 inhibits cytokine-induced IκB-α phosphorylation and thereby 
blocks NF-κB activation. 173 
Cell culture media (DMEM and RPMI-1640), fetal bovine serum (FBS), 
and antibiotics (penicillin G sodium and streptomycin sulfate) were from Gibco 
BRL, distributed by Invitrogen. Medium 199 was from Biomol, and endothelial 
growth medium from PromoCell. Accutase was obtained from PAA Laboratories. 
CellFix and CellWash buffer was from Becton Dickinson. All other reagents were 
from Sigma Chemical Co.  
Cell culture ware was obtained from Nunc Labware. 
 
3.2. Cell Lines 
 
Experiments were performed using the endothelial cell line EA.hy 926 
cells and the monocytic cell line THP-1. To reproduce the most important findings 
using primary human endothelial cells, selected experiments were repeated using 
freshly isolated human umbilical vein endothelial cells (HUVEC).  
EA.hy 926 cells 174, derived by fusing human umbilical vein endothelial 
cells with the permanent human cell line A549/8, were a gift from Dr. Cora Edgell, 
University of North Carolina, Chapel Hill, NC, USA. Passages 30 to 40 were used 
in this study. These cells are widely used to study endothelial cell specific gene 
expression and endothelial cell-leukocyte interactions. EA.hy 926 cells express 
endothelial cell markers like endoglin, tissue factor, thrombomodulin 175, adhesion 
molecules 175 and secrete chemokines 176,177. Cells were maintained in DMEM 
containing 4,500mg\L D-glucose, 10% heat-inactivated FBS, and antibiotics (100 
units/mL penicillin G sodium and 100 µg/mL streptomycin sulfate). Culture plates 
were maintained in a humidified incubator at 37°C w ith a 5% CO2 atmosphere. 
Cells were subcultured after treatment with 0.05% trypsin and 0.53 mmol/L 
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disodium EDTA. Cells were seeded in culture flasks or in 2-well cover slides, and 
allowed to grow to confluence before experimental treatment.  
Primary human umbilical vein endothelial cells (HUVEC) were isolated 
and cultivated in 25 cm2 culture plates in medium 199 containing 
penicillin/streptomycin and 10% FBS mixed with endothelial cell growth medium 
(1:1, vol/vol) as previously described. 178 Passages two and three were used for 
the experiments. 
The human monocytic leukemia cell line, THP-1 (ATCC number TIB-202), 
was used as a model for monocytic cells 179. Cells were cultured in RPMI-1640 
supplemented with 10% FBS and antibiotics (100 units/mL penicillin G sodium and 
100 µg/mL streptomycin sulfate). 
 
3.3. Fluorescent Labeling of Monocytes 
 
For quantitative adhesion assays, THP-1 cells were fluorescently labeled 
with BCECF/AM. 161 BCECF/AM is a variable mixture of at least two compounds, 
which are cell-permeable ester derivatives of BCECF. BCECF/AM is non-
fluorescent, colorless and lipophilic. It is intracellularly cleaved by esterases to 
yield the highly charged fluorescent BCECF that is retained by viable cells. This 
compound has been used to monitor intracellular pH changes in mammalian 
fibroblasts, gastric cells, lymphocytes and myocytes. Typical loading buffer 
contains 1-10 µmol/L BCECF/AM in serum-free media, which is free of amino 
acids and buffers containing primary or secondary amines.  
THP-1 cells were washed three times in serum-free Hank’s balanced salt 
solution (HBSS) and pelleted by centrifugation with a Beckman Coulter centrifuge 
(GH 3.8) for 5 minutes, 800 rpm, at room temperature. 1 x 107 cells/mL were 
incubated with 1 µmol/L BCECF/AM in serum free HBSS (prepared as 1 mg/mL 
stock in anhydrous DMSO and stored at -20°C) for 30 min utes at 37°C and 5% 
CO2. Cells were then washed three times with HBSS containing 2 mmol/L Ca
2+, 2 
mmol/L Mg2+, 20 mmol/L HEPES and 5% FBS to remove excess dye and 
resuspended in RPMI-1640 supplemented with 5% FBS at a density of 5 x 105  
cells/mL. BCECF/AM is also used for apoptotic tests. An influence of this dye 
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when is used under the conditions described above, on the viability or activation of 
cells has not been reported so far. 161 
 
3.4. Static Adhesion Assay 
 
Adhesion of THP-1 cells to treated endothelial cells was studied under 
static conditions. 180 Briefly, endothelial cells were cultured to confluence in 2-well 
cover slides and treated with varying concentrations of D,L-homocysteine, L-
homocysteine, D-homocysteine and L-cysteine, and the respective positive (TNFα, 
50 ng/mL) and negative controls (plain medium) for the indicated periods of time. 
After incubation, endothelial cells were washed twice with phosphate buffered salt 
solution containing calcium and magnesium (PBS++) for avoiding detachment of 
cells from the culture plate.  
BCECF-labeled THP-1 cells (5 x 105 cells/mL/well) were coincubated with 
endothelial cells for 30 minutes at 37°C under slight a gitation on a rotating 
platform. After coincubation, non-adherent cells were removed by gentle washing 
of each well three times with HBSS++ (containing 2 mmol/L Ca2+, 2 mmol/L Mg2+, 
20 mmol/L HEPES). Adherent cells were fixed with 2% glutardialdehyde in 
HBSS++ and visualized using a fluorescence microscope. Ten microscopic fields 
were randomly selected; photodocumented and fluorescent cells were counted.  
In selected experiments, endothelial cells were incubated for 6 hours with 
homocysteine and the respective controls, followed by one hour incubation with an 
anti-human ICAM-1 antibody (2 µg/mL) or the respective isotype control antibody 
before addition of THP-1 cells. The monoclonal anti-ICAM-1 (CD54) antibody 
(clone 8.4A6) used is an IgG1 isotype and recognizes the epitope localized in the 
D2 domain of this cell surface molecule and is recommended to study ICAM-1 
mediated monocyte adhesion. 181  
To evaluate the role of the cellular redox state in the adhesion of 
mononuclear cells on homocysteine incubated endothelial cells, endothelial cells 
cultured in 2-well cover slides were coincubated with D,L-homocysteine 200 
µmol/L and 50 µmol/L MnTBAP or 4 mmol/L Tiron, respectively for 6 hours at 
37°C before static adhesion assays were performed. MnTBA P is a cell-permeable 
superoxide dismutase (SOD) mimetic and peroxynitrite scavenger but does not 
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scavenge nitric oxide (NO). Tiron is a cell-permeable superoxide scavenger. After, 
adhesion assays were performed as described above, adherent cells were 
counted. 
In another set of experiments THP-1 cells were incubated 4 hours with 
varying test substances including homocysteine to induce phenotypic changes. 
After several washing steps, THP-1 cells were labeled with BCECF and the 
functional role of monocyte incubation with homocysteine was studied by 
coincubating them with native endothelial cells and quantifying adherent 
monocytes as described above.  
In selected experiments, THP-1 cells were preincubated for 4 hours with 
sepiapterin followed by 4 hours incubation with homocysteine. The role of the 
cellular redox state in the adhesion of homocysteine incubated mononuclear cells 
on unstimulated endothelial cells was tested by 4 hours coincubation with Tiron 
and homocysteine. For blocking studies THP-1 cells were incubated for 4 hours 
with homocysteine, followed by 1 hour incubation with IgG1 (for blocking the 
unspecific sites) and another hour with an anti-human LFA-1β antibody (2 µg/mL) 
or the respective IgG isotype control. 
 
3.5. Determination of Cell Adhesion Molecules Expre ssion by  
Flow Cytometry 
 
The expression levels of the adhesion molecules ICAM-1, VCAM-1, E-
selectin, and PECAM-1 on homocysteine-treated EA.hy 926 cells and HUVECs 
were quantified by flow cytometry. Cell monolayers cultured in P60 dishes were 
washed with phosphate-buffered saline without calcium and magnesium (PBS--) 
and incubated with Accutase for 5 minutes at 37°C until the cells were detached 
from the culture dish. Accutase is a mixture of proteolytic and collagenolytic 
enzymes from non-mammalian source (free of viruses common in trypsin) used for 
detaching adherent cells. After collecting from the plates, the cells were treated 
with CellFix (Becton Dickinson), pelleted by centrifugation and resuspended in 
PBS + 1% bovine serum albumin for blocking unspecific sites. After resuspension, 
cells were reacted with mouse anti-human ICAM-1, anti-human VCAM-1, anti-
human PECAM-1 and anti-human E-selectin antibodies. After washing procedure, 
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the cells were labeled with rabbit anti-mouse FITC-labeled immunoglobulins, 
washed, and the fluorescence of ten thousands cells was measured on a 
FACScan flow cytometer (Becton Dickinson).  
The expression levels of β2-integrins LFA-1β and Mac-1α on THP-1 cells 
were also quantified by flow cytometry. THP-1 cells were washed with PBS--, 
treated with CellFix, and pelleted by centrifugation. After resuspension in 
CellWash buffer, cells were labeled with the respective FITC-labeled antibodies 
(anti-human LFA-1β and Mac-1α).  
Data analysis was performed with CellQuest software (Becton Dickinson). 
The median of the specific fluorescence intensity was used as a marker for 
expression of the respective epitope. Nonspecific fluorescence was detected by 
using isotype-matched nonbinding antibody (Mouse IgG1, Kappa - MOPC-21) and 
subtracted.  
 
3.6. Measurement of Intracellular Reactive Oxygen S pecies  
Generation in Homocysteine-Treated Endothelial Cell s and  
Monocytes 
 
The intracellular generation of reactive oxygen species was evaluated by 
monitoring the oxidative conversion of the fluorophore dichlorofluorescein (DCF) 
as described previously 182. DCF is used for the detection of reactive oxygen 
species (ROS) and for the determination of the degree of overall oxidative stress. 
183 The diacetate of DCF (DCF-DA) is a cell-permeable modification of this 
fluorogenic probe, which rapidly enters cells due to its lipophicity. Intracellularly, 
the ester bonds are cleaved, resulting in a more hydrophilic compound (DCF) 
which is retained in the cells. Briefly, EA.hy 926 cells, grown to confluence on two-
well cover slides, were incubated with the test substances for 6 hours and then 
loaded for 15 minutes at 37°C at darkness with the me mbrane-permeable dye 
DCF-DA (10 µmol/L) in modified Tyrode’s buffer (135 mmol/L NaCl, 2.7 mmol/L 
KCl, 1.8 mmol/L CaCl2, 0.28 mmol/L NaH2PO4, 0.49 mmol/L MgCl2, 5.5 mmol/L D-
Glucose, 20 mmol/L HEPES, pH = 7.4). After washing the cells several times, the 
intracellular fluorescence intensities (excitation 488 nm, emission >515 nm) were 
measured in several regions of interest using a confocal laser scanning 
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microscope (LSM 410 Invert, Zeiss). Values obtained were expressed as arbitrary 
fluorescent units relative to control conditions. Thrombin-receptor activating 
peptide (TRAP, Bachem) 10 µmol/L was used as positive control. The peptidic 
sequence of TRAP is H-Ser-Phe-Leu-Leu-Arg-Asn-NH2. 
To monitor the intracellular generation of reactive oxygen species inside 
THP-1 cells, THP-1 cells were incubated with the test substances for 4 hours. 
After washing, cells were incubated in modified Tyrode’s buffer containing 10 
µmol/L DCF-DA for 15 minutes at 37°C, in the dark. T HP-1 cells loaded with DCF-
DA and incubated for 15 minutes at 37°C with 10 mmol/ L H2O2 were used as 
positive control for the method. The fluorescence intensities were measured by 
flow cytometry (excitation 488 nm, emission >515 nm). Nonspecific fluorescence 
was detected by using unstained cells and substracted. 
The superoxide release from homocysteine-incubated THP-1 cells was 
detected by the L-012 chemiluminescence assay. 184 Briefly, THP-1 cells were 
incubated with the test substances for 4 hours. After washing, cells were 
resuspended in modified Tyrode’s buffer at the density of 50.000 cells per 330 µl. 
In each tube 30 µl of L-012 (100 µmol/L) was added just before measuring the 
luminescence. The kinetics of oxidative burst in homocysteine-incubated THP-1 
cells was recorded with a Lumat 9507 on addition of L-012. Photon emission was 
expressed as percent increase in relative light units versus control conditions. 
 
3.7. Isolation of Total RNA and Real-time RT-PCR fo r ICAM-1 RNA  
Expression by Endothelial Cells 
 
EA.hy 926 cells were cultured to confluence in P100 dishes and 
incubated for 6 hours at 37°C with the test  substances. After washing with PBS 
the cells were lysed directly in a culture dish by adding 3 mL of TRIZOL Reagent 
(Gibco BRL), and passing the cell lysate several times through a pipette.  
TRIZOL is a monophasic solution of phenol and guanidine isothiocyanate. 
Addition of chloroform followed by centrifugation, separates the solution into an 
aqueous phase and an organic phase. RNA remains exclusively in the aqueous 
phase. After transfer of the aqueous phase, the RNA is recovered by precipitation 
with isopropyl alcohol. At the end, RNA is dissolved in 60 µl (30 µl/tube) RNase-
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free water by passing the solution a few times through a pipette tip and incubated 
for 10 minutes at 60°C. The RNA concentration was dete rmined 
spectrophotometrically and the samples were stored at -80°C. 
Real time RT-PCR was performed as previously described 185 using the 
dsDNA-binding dye SYBR Green I and the TaqMan ABI 7700 Sequence Detection 
System (AppliedBiosystems) for real time quantification 185. Briefly, 1 µg of total 
RNA was reverse transcribed in a 40 µl reaction, containing 8 µl first strand buffer 
(5x), 2 µl 100 mmol/L DTT (both Life technologies), 0.8 µl 25 mmol/L dNTP 
(Amersham Pharmacia), 1 µl RNase inhibitor (RNasin, Promega), 0.5 µl 
Microcarrier (Molecular Research Center), 0.86 µg random hexamers (2 mg/mL 
stock, Roche), and 172 U reverse transcriptase (Superscript I, Life technologies) 
for one hour at 42°C. Sequence specific amplification was done using heat 
activated TaqDNA polymerase (Amplitaq Gold, Applied Biosystems) and 
oligonucleotide primers specific for human ICAM-1 cDNA (forward primer: 5’ 
TGGCAACGACTCCTTCTCG; reverse primer: 5’ 
AGCTGTAGATGGTCACTGTCTGCA, 300 nmol/L each) on a TaqMan ABI 7700 
Sequence Detection System (AppliedBiosystems). After an initial denaturation 
step for 10 minutes at 95°C, the samples were cycled 40  times at 95°C for 15 
seconds and 60°C for 60 seconds 186 For all quantitative analyses cDNA content 
of each sample was compared with another sample following the ∆∆Ct technique 
or standard curves, respectively. 18S rRNA and Cyclophilin A, which served as 
housekeeping genes, were amplified in parallel with the genes of interest. Primers 
for the genes of interest were designed in PrimerExpress and searched against 
the public databases to confirm unique amplification products. Controls consisting 
of ddH2O were negative in all runs. All measurements were performed in 
duplicates.  
 
3.8. Immunofluorescent Detection of NF- κB Translocation 
 
Activation of NF-κB was determined by assessing the distribution of its 
subunit p65 between cytoplasm and the nucleus of EA.hy 926 cells in 
immunofluorescence images as described 187.  
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Briefly, confluent EA.hy 926 cells were cultured in 2-well cover slides and 
treated with the test substances as indicated. Cells were then washed with PBS++, 
fixed with 2% formalin solution and subsequently permeabilized by submersion in 
0.2% Triton X-100. After washing again three times with PBS++ and blocking the 
unspecific sites with Blocking Buffer for 10 minutes at room temperature, under 
slight agitation, the samples were then incubated with the primary antibody (rabbit 
anti human p65 subunit) 45 minutes at 37°C, and fina lly treated with the 
secondary antibody (FITC labeled, goat anti rabbit) for 30 minutes at 37°C.   
Fluorescence intensities were detected using a confocal microscope 
(LSM 410 Invert, Zeiss) and the cellular distribution of p65 was measured as the 
ratio of its fluorescence in nucleus/cytoplasm. 
 
3.9. Statistical Analysis 
 
Values are reported as means ± SEM. Differences in time-responses and 
dose-responses to the test substances between groups were tested with two-way 
repeated measures ANOVA with posthoc anaylsis performed using Fisher’s test 
and Bonferonni/Dunn procedures. Other data were analyzed by factorial ANOVA 
and posthoc comparisons. Analyses were performed using the STATVIEW software 
package (Abacus Concepts). Statistical significance was defined as a P value less 
than 0.05. 
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4. RESULTS 
4.1. Effects of Homocysteine on Endothelial Cells 
4.1.1. Time- and Dose-Dependent Increase in Monocyt e Adhesion to 
Homocysteine-Incubated Endothelial Cells 
 
Incubation of EA.hy 926 cells with 200 µmol/L D,L-homocysteine for 30 
minutes to 24 hours resulted in a time-dependent increase in the number of 
adhering THP-1 cells compared to baseline THP-1 monocyte adhesion to 
unstimulated EA.hy 926 monolayers (baseline: 7.6 ± 1.7 cells per microscopic 
field). The effect of homocysteine on the adhesion was statistically significant from 
baseline between 3 and 8 hours of incubation, peaked after 6 hours (28.2 ± 1.1 
cells per microscopic field), and declined thereafter. All further experiments were 
performed with incubation times of 6 hours.    
Incubation of EA.hy 926-cells with increasing concentrations of D,L-
homocysteine (10 to 200 µmol/L) for 6 hours leads to a dose-dependent and 
significant increase in the number of adhering THP-1 cells to endothelial cells up 
to a 4.5 fold at the highest concentration studied compared to control conditions 
(control: 5.9 ± 1.2 cells per microscopic field, D,L-homocysteine 200 µmol/L: 33.1 ± 
5.6 cells per microscopic field; n = 5 experiments; *P < 0.05). Incubation with L-
cysteine had no significant effect (Figure 9). 
These findings were reproduced using primary human endothelial cells 
(HUVEC) incubated with 200 µmol/L homocysteine (control: 7.5 ± 0.96 cells per 
microscopic field, D,L-homocysteine 200 µmol/L: 26.33 ± 0.75 cells per 
microscopic field; n = 3 experiments; *P < 0.05). 
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                   A 
                                                        B 
Figure 9.  A – Representative photomicrographs of static adhesion assays. TNF-α and 
homocysteine stimulation of EA.hy 926 cells lead to a significant increase in adhesion of 
fluorescence labeled monocytes. B – Quantitative analysis of dose-dependent adhesion of 
monocytes to homocysteine-incubated EA.hy 926 cells. Six hours incubation of endothelial cells 
with increasing concentrations of D,L-homocysteine leads to a dose-dependent increase in 
adherent monocytes up to four-fold compared to control conditions. L-cysteine had no effect. TNF-
α (50 ng/mL) was used as positive control. (n = 5 experiments; *P < 0.05 vs. control)     
 
4.1.2. Stereospecific Increase in Monocyte Adhesion  to  
Homocysteine–Incubated Endothelial Cells 
 
To examine whether the effect of homocysteine is stereospecific for the 
natural occurring L-isoform, or independent from the stereoisoform, endothelial 
cells were incubated with 200 µmol/L D,L-, L-, or D-homocysteine.  
Incubation of endothelial cells with D,L-homocysteine and L-homocysteine 
dose-dependently and significantly increased monocyte adhesion to endothelial 
cells up to almost fivefold compared to control. In contrast, D-homocysteine had no 
significant effect, indicating that the stimulatory effects of homocysteine are 
specific for the naturally occurring L-stereoisomer. (Figure 10) 
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Figure 10.  Stereospecific effect of L-homocysteine on monocyte adhesion to EA.hy 926 
cells. Incubation of endothelial cells with different stereoisomers of homocysteine only lead to 
significantly increased monocyte adhesion using the naturally occuring L-homocysteine, and D,L-
homocysteine, but not using D-homocysteine. (n = 4 experiments; *P<0.05 vs. control)    
 
4.1.3. Adhesion Molecules Expression on Homocystein e–Stimulated 
Endothelial Cells  
 
The endothelial expression of adhesion molecules, like "CAMs" or 
"selectins", are known to mediate monocyte adhesion to endothelial cells. To 
explore which adhesion molecule might be involved in homocysteine-induced 
monocyte adhesion to endothelial cells, the expression levels of different adhesion 
molecules on endothelial cells were studied in untreated and homocysteine-
incubated endothelial cells (200 µmol/L for 6 hours) using FACS analysis.  
D,L- and L-homocysteine-incubated EA.hy 926 cells and HUVECs showed 
a significant increase in ICAM-1 protein expression (Table 3). This effect was 
specific for homocysteine but not for other thiols, and was specific for the L-
stereoisomer of homocysteine, as D-homocysteine and L-cysteine (200 µmol/L for 
6 hours) respectively, had no effect on either of the adhesion molecules tested. 
VCAM-1, PECAM-1, or E-selectin protein expression was not stimulated by any 
homocysteine species used (data not shown). 
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Table 3. Relative ICAM-1 expression on EA.hy 926 cells and HUVECs as determined by 
flow cytometry. Values indicate mean ± SEM, n = 4 experiments, *P < 0.05 vs. control. 
 
 
Condition 
ICAM-1 expression 
(% Control) 
on EA.hy 926 cells 
ICAM-1 expression 
(% Control) 
on HUVECs 
Control 100 ± 0 100 ± 0 
D,L-homocysteine 200µmol/L 130.6 ± 6.5 * 163.4 ± 9.8 * 
L-homocysteine 200µmol/L   146.1 ± 12.9 *  
D-homocysteine 200µmol/L 101.2 ± 12.4  
 
To examine, whether increased ICAM-1 protein expression on endothelial 
cells is regulated on a transcriptional level, ICAM-1 mRNA levels were monitored 
by real time RT-PCR. Incubation of EA.hy 926 cells with L-homocysteine (200 
µmol/L for 6 hours) lead to significant increase in ICAM-1 mRNA levels compared 
to control (131 ± 7 % of control; n = 4 experiments; P < 0.05). Incubation with L-
cysteine had no effect (108 ± 8 % of control; n = 4 experiments). 
To confirm the functional relevance of increased ICAM-1 expression on 
monocyte adhesion to homocysteine-incubated endothelial cells, EA.hy 926 and 
HUVECs, respectively, were incubated with 200 µmol/L D,L-homocysteine for 6 
hours, followed by one hour incubation with IgG1 Ab (for blocking the unspecific 
sites) and then one hour with a blocking antibody against human ICAM-1 or the 
respective isotype control, and monocyte adhesion assays were performed.  
Preincubation with an anti-ICAM-1 antibody markedly reduced 
homocysteine-induced monocytes adhesion to endothelial cells (from 26.33 ± 0.75 
to 12.18 ± 0.51 in HUVECs, and from 25.75 ± 0.854 to 11.25 ± 2.394 in EA.hy 926 
cells, respectively; n = 3 experiments, $P < 0.05), but did not bring it back to 
control levels. (Figure 11)  
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Figure 11. Monocyte adhesion to homocysteine-incubated EA.hy 926 cells could be 
blocked by an anti-human ICAM-1 antibody. (n = 4 experiments,*P<0.05 vs. control, $P<0.05 vs. 
D,L-homocysteine 200µmol/L) 
 
These experiments show that an increase in ICAM-1 expression is at 
least partly responsible for homocysteine’s effects on monocyte adhesion to 
endothelial cells. 
 
4.1.4. Dose-Dependent and Stereospecific Generation  of Intracellular  
Reactive Oxygen Species in Homocysteine-Incubated E ndothelial  
Cells 
 
One well-supported but not universally accepted hypothesis suggests that 
elevated levels of homocysteine lead to increased vascular oxidant stress, which 
may result in endothelial dysfunction.  
To monitor the intracellular generation of reactive oxygen species, EA.hy 
926 cells grown on cover slides were incubated with increasing concentrations of 
D,L-homocysteine (20 to 200 µmol/L), L-cysteine (200 µmol/L) or sham treated, 
loaded with the redox-sensitive dye DCF-DA, and the intracellular fluorescence 
intensities were measured after 6 hours using a confocal laser scanning 
microscope. Homocysteine-incubation resulted in a dose-dependent and 
significant increase in intracellular fluorescence indicative of increased generation 
of reactive oxygen species (RFU 248 ± 24% of control at 50 µmol/L D,L-
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homocysteine and 360 ± 33% of control at 200 µmol/L D,L-homocysteine; P < 
0.05). L-cysteine had no significant effect (RFU 174 ± 18% of control). Thrombin-
receptor activating peptide (TRAP, 10 µmol/L) was used as a positive control. 
(Figure 12). 
 
 
 
Figure 12.  Dose-dependent increase in reactive oxygen species in homocysteine-
incubated EA.hy 926 cells. Six hours incubation of endothelial cells with homocysteine dose-
dependently increases the fluorescence of the reactive oxygen species-sensitive dye DCF in 
cultured endothelial cells. EA.hy 926 cells were incubated with different concentrations of 
homocysteine and L-cysteine, respectively, for 6 hours. TRAP 10 µmol/L was used as a positive 
control. After loading with DCF-DA, intracellular DCF-fluorescence was visualized using confocal 
laser microscopy and quantified by image analysis. The right panel shows the mean ± SEM 
fluorescence intensity of three experiments, and the left panel shows representative fluorescence-
microscopy images. (n = 3 experiments, *P < 0.05 vs. control) 
 
4.1.5. Enhanced NF- κB Translocation in Homocysteine-Incubated  
Endothelial Cells 
 
Previous experiments suggested that oxidant stress to EC due to 
hyperhomocysteinemia may result in increased activation of the redox-sensitive 
transcription factor NF-κB 188.  
To study whether or not this may be involved in increased adhesion 
molecule expression, NF-κB activation in homocysteine-incubated endothelial 
cells was studied by measuring the translocation of the NF-κB p65 subunit from 
cytosol to the nucleus using immunofluorescence techniques. Incubation of EA.hy 
926 cells with 200 µmol/L D,L-homocysteine for 6 hours resulted in significantly 
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increased nuclear staining for the p65 subunit (nucleus/cytosol ratio 2.12 ± 0.31* 
comparing with control 1.52 ± 0.34, *P < 0.05 vs. control), showing increased 
nuclear translocation. In contrast, L-cysteine had no effect (nucleus/cytosol ratio 
1.24 ± 0.24). (Figure 13) 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.  Homocysteine increases nuclear NF-κB translocation in endothelial cells. Six 
hours incubation of EA.hy 926 cells with D,L-homocysteine 200 µmol/L leads to increased nuclear 
NF-κB translocation, as evident by increased nuclear staining with an anti-p65-antibody. L-cysteine 
had no significant effect. TNF-α 50 ng/mL was used as positive control. The values are expressed 
as nucleus/cytosol ratio ± SEM fluorescence intensity of three experiments *P< 0.05 vs. control. 
(Control 1.52 ± 0.34; TNF-α 3.31 ± 0.51; D,L-homocysteine 2.12 ± 0.31*; L-cysteine 1.26 ± 0.24) 
 
Increased NF-κB activation in homocysteine-incubated endothelial cells 
could be reproduced using HUVEC (Figure 14). The specificity of the increased 
nuclear staining with an antibody against the p-65 subunit of NF-κB could be 
shown by using the synthetic inhibitor of NF-κB translocation Bay 11-7082 in 
combination with homocysteine. 
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Figure 14.  Homocysteine increases nuclear NF-κB translocation in endothelial cells. Six 
hours incubation of HUVEC with D,L-homocysteine 200 µmol/L leads to increased nuclear NF-κB 
translocation, as evident by increased nuclear staining with an anti-p65-antibody. L-cysteine had no 
significant effect. Bay 11-7082 (10 µmol/L) inhibited homocysteine-induced NF-κB translocation. 
TNF-α 50 ng/mL was used as positive control. The values are expressed as nucleus/cytosol ratio ± 
SEM fluorescence intensity of three experiments *P< 0.05 vs. control; $P<0.05 vs. D,L-
homocysteine. (Control 0.69 ± 0.02; TNF-α 3.96 ± 0.28; D,L-homocysteine 1.9 ± 0.14*; D,L-
homocysteine+Bay 0.77 ± 0.01$; L-cysteine 0.70 ± 0.01) 
 
 
4.1.6. Effect of Scavenging of Superoxide Anion on Homocysteine-               
Induced Monocyte Adhesion, Adhesion Molecule Expres sion and  
NF-κB Translocation 
 
To test the influence of oxidative stress on the adhesion of THP-1 cells to 
homocysteine-incubated endothelial cells, endothelial monolayer was coincubated 
with homocysteine and MnTBAP (superoxide dismutase mimetic complex) or 
Tiron.  
Coincubation of EA.hy 926 cells with homocysteine and with either 
MnTBAP or Tiron completely prevented homocysteine-induced increase in 
monocyte adhesion to endothelial cells (Figure 15). 
Coincubation of HUVECs with homocysteine and Tiron almost completely 
prevented homocysteine-induced increase in monocyte adhesion to endothelial 
cells (from 26.33 ± 0.75 to 9.67 ± 0.35 cells per microscopic field). 
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Figure 15. Incubation of EA.hy 926 cells with D,L-homocysteine together with the 
superoxide dismutase mimetic complex MnTBAP or Tiron abolished homocysteine’s stimulatory 
effect on monocyte adhesion. (n = 4 experiments, *P < 0.05 vs. control $P < 0.05 vs. D,L-
homocysteine 200 µmol/L) 
 
Scavenging of superoxide anion also prevented homocysteine-induced 
increase in endothelial ICAM-1 expression (Table 4).  
 
Table 4. ICAM-1 expression on endothelial cells coincubated with homocysteine and 
antioxidants as determined by flow cytometry. Values indicate mean ± SEM, n = 4 experiments, *P 
< 0.05 vs. control, $P < 0.05 vs. D,L-homocysteine. 
 
 
Condition 
ICAM-1 
expression 
(% Control) on 
EA.hy 926 cells 
ICAM-1 
expression 
(% Control) on 
HUVECs 
Control 100 ± 0 100 ± 0 
Control+Tiron 98.7 ± 5.8 99.4 ± 2.7 
Control+MnTBAP 99.6 ± 5.1  
D,L-homocysteine 200µmol/L 130.6 ± 6.5 * 163.4 ± 9.8 * 
D,L-homocysteine 200µmol/L+Tiron 102.4 ± 3.8 $ 106.0 ± 0.1 $ 
D,L-homocysteine 200µmol/L+MnTBAP 101.6 ± 4.1 $  
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In addition, pretreatment of endothelial cells with the superoxide 
scavenger Tiron abolished the increased nuclear translocation of NF-κB induced 
by homocysteine in EA.hy 926 cells (Figure 16) and in HUVEC (Table 5). 
 
       
 
Figure 16. Incubation of EA.hy 926 cells with D,L-homocysteine together with Tiron 
abolished homocysteine-induced translocation of NF-κB from cytoplasm to the nucleus. The values 
are expressed as nucleus/cytosol ratio ± SEM fluorescence intensity of three experiments. *P < 
0.05 vs. control; $P < 0.05 vs. D,L-homocysteine.  
 
 
Table 5. Incubation of HUVECs with D,L-homocysteine together with Bay 11-7082 or 
Tiron abolished homocysteine-induced translocation of NF-κB from cytoplasm to the nucleus. TNF-
α was used as positive control. The values are expressed as nucleus/cytosol ratio ± SEM 
fluorescence intensity of three experiments. (*P<0.05 vs. control, $P<0.05 vs. D,L-homocysteine) 
 
 
Condition 
Nucleus/Cytoplasm 
Ratio 
Control 0.69 ± 0.02 
TNF-α 3.96 ± 0.28 
D,L-homocysteine 200 µmol/L 1.90 ± 0.14 * 
D,L-homocysteine 200 µmol/L+Tiron 0.73 ± 0.03 $ 
D,L-homocysteine 200 µmol/L+ Bay 11-7082 0.77 ± 0.01 $ 
L-cysteine 200 µmol/L 0.70 ± 0.01  
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These findings indicate that the effects of homocysteine on endothelial 
cell activation leading to increased monocyte adhesion are at least partly due to 
increased superoxide anion production. Antioxidant treatment restores the normal 
function of endothelial cells and stops promoting the redox-sensitive NF-κB 
signaling cascade induced by reactive oxygen species formation under 
hyperhomocysteinemic conditions. 
 
4.1.7. Inhibition of Homocysteine-Induced NF- κB Activation in  
Endothelial Cells Prevents ICAM-1 Expression and Mo nocyte  
Adhesion 
 
To further confirm that increased NF-κB activation under conditions of 
elevated homocysteine mediates increased ICAM-1 expression on endothelial 
cells and increased monocyte adhesion to endothelial cells, HUVEC were 
incubated with homocysteine and the inhibitor of NF-κB activation Bay 11-7082, 
which completely suppresses homocysteine-induced NF-κB translocation (Table 
5), and flow cytometry and adhesion studies were performed. 
Data show that homocysteine requires NF-κB for its stimulatory effect on 
endothelial cells because inhibition of NF-κB translocation by Bay 11-7082 
blocked the expression of ICAM-1 (from 163.4 ± 9.8 % of control for D,L-
homocysteine 200 µmol/L to 102.4 ± 0.2 % of control for D,L-homocysteine 200 
µmol/L + Bay 11-7082) and the adhesion of monocytes (from 26.33 ± 0.75 to 9.72 
± 0.24 cells per microscopic field).  
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4.2. Effect of Homocysteine on Circulating Mononucl ear Cells 
 
4.2.1. Stereospecific Increase in Adherent Homocyst eine–Treated  
Monocytes to Unstimulated Endothelial Cells  
 
Incubation of THP-1 cells with up to 200 µmol/L D,L- homocysteine and L-
homocysteine for 4 hours resulted in a significant increase in the number of 
adhering THP-1 cells to unstimulated EA.hy 926 monolayers up to 3 fold at the 
highest concentration studied compared to control conditions (control: 9.17 ± 0.7 
cells per microscopic field, D,L-homocysteine 200 µmol/L: 25.83 ± 1.94 cells per 
microscopic field; L-homocysteine 200 µmol/L: 26.4 ± 1.86; L-homocysteine 100 
µmol/L: 22.3 ± 2.16). Incubation of THP-1 cells with L-cysteine (200 µmol/L) and D-
homocysteine (200 µmol/L and 100 µmol/L) had no significant effect, indicating 
specificity for homocysteine and stereospecificity for the L-stereoisomer (Figure 
17). 
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Figure 17.  Stereospecific increase in the number of adhering homocysteine-incubated 
monocytes to unstimulated endothelial cells. Incubation of THP-1 cells with different stereoisomers 
of homocysteine only leads to significantly increased monocyte adhesion using the naturally 
occuring L-homocysteine, and D,L-homocysteine, but not using D-homocysteine (n = 5 experiments; 
*P<0.05 vs. control) 
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4.2.2. Adhesion Molecules Expression on Homocystein e-Activated  
Monocytes 
 
The integrin family of CAMs which are expressed on monocytes, serve as 
ligands for the ICAMs and VCAMs expressed on endothelial cells. The integrins 
are heterodimeric proteins consisting of an alpha and a beta chain that mediate 
leukocyte adherence to the vascular endothelium or other cell-cell interactions. 
Different sets of integrins are expressed by different populations of leukocytes to 
provide specificity for binding to different types of CAMs expressed along the 
vascular endothelium.  
To explore whether integrins might be involved in homocysteine-induced 
monocyte adhesion to EA.hy 926 cells, the expression of β2-integrins on 
monocytes was studied in untreated and homocysteine-incubated THP-1 cells 
(200 µmol/L for 4 hours) using FACS analysis. D,L- and L-homocysteine-incubated 
THP-1 cells showed almost 40% increase in LFA-1β (143.6 ± 9.2 % of control, n = 
4 experiments, P<0.05 vs. control) and Mac-1α (134.9 ± 12.7 % of control, n = 4 
experiments, P<0.05 vs. control). This effect was specific for homocysteine but not 
for other thiols, and was specific for the L-stereoisomer of homocysteine, as D-
homocysteine and L-cysteine, respectively, had no effect.  
To confirm the functional relevance of increased β-2 integrin expression 
on homocysteine-incubated monocyte adhesion to endothelial cells, THP-1 cells 
were incubated with 200 µmol/L D,L-homocysteine for 4 hours, followed by 
incubation with an blocking antibody against human LFA-1β or an isotype matched 
control antibody. After that monocyte adhesion assays were performed. Blocking 
LFA-1β significantly reduced homocysteine-induced monocytes adhesion to 50% 
(Figure 18).  
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Figure 18.  Homocysteine stimulatory effect on monocyte adhesion could be blocked by 
an anti-human LFA-1β antibody (from 20 ± 0.32 to 10.37 ± 0.79 adherent cells per microscopic 
field, n = 4 experiments, *P<0.05 vs. control, $P<0.05 vs. D,L-homocysteine 200µmol/L). 
 
These data indicate that an homocysteine-induced increase in β-2 integrin 
expression on monocytes is involved in the homocysteine’s stimulatory effect on 
monocyte adhesion. 
 
4.2.3. Nitric Oxide Synthase Dependent Generation o f Intracellular  
Reactive Oxygen Species in Homocysteine-Activated M onocytes 
 
To monitor the intracellular generation of ROS inside homocysteine-
stimulated mononuclear cells, THP-1 cells were incubated for 4 hours with D,L-
homocysteine 200 µmol/L, L-cysteine 200 µmol/L, loaded with the redox-sensitive 
dye DCF-DA, and the intracellular fluorescence intensities were measured by flow 
cytometry. Homocysteine-incubation resulted in a dose-dependent and significant 
increase in intracellular fluorescence indicative of increased generation of ROS 
(132 ± 6.4% relative fluorescence units of control) (Figure 19).  
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Figure 19.  Reactive oxygen species generation in homocysteine-incubated THP-1 cells 
stained with DCF-DA and measured by flow cytometry. (n = 4 experiments, *P<0.05 vs. control, 
$P<0.05 vs. D,L-homocysteine 200µmol/L) 
 
To further evaluate whether ROS production in THP-1 cells stimulated 
with homocysteine is dependent on nitric oxide synthase, the cells were 
coincubated with the competitive inhibitor of NOS L-NAME, which inhibits both NO 
synthesis and superoxide anion production, and L-NMMA, which inhibits nitric 
oxide synthesis but not superoxide anion production, or with sepiapterin, an 
synthetic precursor of BH4 which is a cofactor for NOS.  
The results presented in figure 19 illustrate that the ROS production in 
monocytes which increased by treatment with D,L-homocysteine 200 µmol/L could 
be significantly attenuated by L-NAME pretreatment (to 115.6 ± 7 % RFU of 
control) but not by L-NMMA (RFU 134.3 ± 8 % RFU of control). Preincubation with 
L-sepiapterin (100µmol/L) before homocysteine treatment reduced ROS levels to 
control (to 102.2 ± 6.1 % RFU of control). 
 
The kinetics of superoxide production in homocysteine-incubated THP-1 
cells was further revealed by luminescence on addition of L-012 (100 µmol/L) and 
expressed as percent increase in relative light units versus control conditions 
(Figure 20). Homocysteine significantly increased the superoxide release from 
THP-1 cells (144  ± 7.4 % RLU of control).  
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Figure 20.  Superoxide production in homocysteine-incubated monocytes expressed as 
percent increase in relative light units versus control conditions. (n = 4 experiments, *P<0.05 vs. 
control, $P<0.05 vs. D,L-homocysteine 200 µmol/L)  
 
Inhibition of NO synthase by incubation of THP-1 cells with homocysteine 
and L-NAME resulted in a significant decrease of superoxide release from THP-1 
cells. Superoxide generation could not be attenuated by coincubation with L-
NMMA, which inhibits nitric oxide production by iNOS but not superoxide 
production. The chemiluminescence of L-012 was significantly decreased by 
coincubation with the antioxidant Tiron. LPS 10 µg/mL was used as positive 
control for amplifying oxidative stress inside THP-1 cells. 
This data show that the induction of superoxide formation in 
hyperhomocysteinemic conditions could involve iNOS in monocytes by depleting 
the cofactors (biopterin stocks) necessary for the activity and nitric oxide 
production.  
 
4.2.4. Effect of Scavenging of Superoxide Anion and  Inhibition of  
iNOS on Homocysteine-Induced Monocyte Adhesion  
 
In support of the role of increased intracellular superoxide generation for 
the above mentioned effects via iNOS dependent mechanisms, pretreatment of 
mononuclear cells with sepiapterin significantly decreased homocysteine-induced 
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monocyte adhesion to unstimulated endothelial cells (from 19,875 ± 0,319 to 
11,063 ± 1,063 cells per microscopic field; Figure 21).  
Incubation of monocytes with D,L-homocysteine together with Tiron 
(4mmol/L) or L-NAME (1mmol/L) significantly diminished homocysteine’s 
stimulatory effect on monocyte adhesion (from 19,875 ± 0,319 for D,L-hcy to 
14,781 ± 2,043 for D,L-hcy + L-NAME and to  7,98 ± 0,362 for D,L-hcy + Tiron). 
Coincubation with L-NMMA (1mmol/L) slightly increased the homocysteine’s 
stimulatory effect on monocyte adhesion (from 19,875 ± 0,319 to 21,375 ± 0,421). 
This indicated that the effects of homocysteine on monocyte activation 
and increased adhesion to endothelial cells, are at least partly due to increased 
superoxide anion production probably by uncoupling of iNOS enzyme. 
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Figure 21. Incubation of monocytes with D,L-homocysteine together with Tiron (4mmol/L) 
or L-NAME (1mmol/L) significantly diminished homocysteine’s stimulatory effect on monocyte 
adhesion. Preincubation with Sepiapterin (100µmol/L) decreased number of adherent cells. 
Coincubation with L-NMMA (1mmol/L) slightly increased the homocysteine’s stimulatory effect on 
monocyte adhesion. (n = 4 experiments, *P < 0.05 vs. control **P < 0.05 vs. D,L-homocysteine 200 
µmol/L) 
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5. DISCUSSION 
Atherosclerosis is viewed as chronic inflammatory process of the vessel 
wall that initiates and promotes lesion development. This process involves 
circulating leukocytes, particularly monocytes, that are recruited and adhere to the 
activated endothelium, and that migrate into the subendothelial space where they 
differentiate into macrophages. 4,189 These recruited macrophages endocytose 
modified forms of LDL via scavenger receptors to form foam cells, the hallmark of 
fatty streak lesions. The lesions develop into fibro-fatty plaques, which contain 
large numbers of macrophages and some CD4+ T cells, and show evidence of 
smooth muscle migration and proliferation. In human arteries, these fibro-fatty 
plaques develop into complex atherosclerotic lesions that are liable to rupture.  
Elevated levels of the amino acid homocysteine are associated with an 
increased risk for atherosclerotic vascular diseases in humans. However, the 
mechanisms by which excess homocysteine is harmful to the vasculature are not 
completely understood as yet. Several hypotheses have been proposed to explain 
the effects of homocysteine. Very high concentrations of homocysteine seem to be 
toxic for endothelial cells 190, whereas pathophysiologically relevant concentrations 
as found in patients with mild hyperhomocysteinemia seem to induce functional 
endothelial changes summarized as endothelial dysfunction. 98 Potential 
pathophysiogical mechanisms have been described in Chapter 1.5. In addition, 
homocysteine has been shown to promote the formation and increase the 
complexity of atherosclerotic lesions in atherosclerosis prone animal models. 
141,191,192  
Because the adhesion and accumulation of leukocytes have been 
demonstrated to be a critical event in the development of atherosclerosis, we 
investigated the effect of homocysteine on the interaction between endothelial 
cells (EA.hy 926 and HUVEC) and monocytes (THP-1 cells). 
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Effects of Homocysteine on the Expression of Proinf lammatory  
Cytokines in Monocytes and Endothelial Cells 
 
Previous in vitro studies have shown that homocysteine is able to induce 
mRNA and protein expression of the proinflammatory cytokines MCP-1 and IL-8 in 
cultured human aortic endothelial cells (HAEC) 140,193 and in (THP-1)-derived 
macrophages 163, whereas it had no effect on expression of other cytokines, like 
tumor necrosis factor-α, granulocyte-macrophage colony–stimulating factor, 
interleukin-1β, and transforming growth factor-β. 140 The increase in MCP-1 
expression was associated with activation of nuclear factor NF-κB due to 
increased phosphorylation of the inhibitory protein (IκB-α) as well as reduced 
expression of IκB-α mRNA in homocysteine-treated THP-1 cells. 163 
This cascade of events triggered increased recruitment of monocytes to 
endothelial cells. The induction of chemokine expression was specific for 
homocysteine, because equimolar concentrations of L-homocystine, L-cysteine, 
and L-methionine had no effect on mRNA levels and protein release. Furthermore, 
L-homocysteine induced chemokine expression, but D-homocysteine did not, thus 
demonstrating enantiomeric specificity. 140 In addition, homocysteine has been 
shown to increase neutrophil adherence to endothelial cells in vitro and in vivo. 194 
This contact results in neutrophil migration across the endothelial layer, with 
concurrent damage and detachment of endothelial cells. This effect seemed to be 
mediated via binding of leukocyte β2-integrins (Mac-1α, CD11b and LFA-1β, 
CD18) to endothelial cells, as the interaction between endothelial cells and 
leukocytes could be abolished using blocking antibodies against these molecules, 
although the authors did not demonstrate any increase in β2-integrin expression 
on leukocytes nor in ICAM-1 expression in homocysteine-incubated endothelial 
cells. 
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Effects of Homocysteine on Adhesion Molecules Expre ssion and  
Monocyte Adhesion to Endothelial Cells 
 
Whether or not incubation of endothelial cells with homocysteine results in 
increased monocyte adhesion to endothelial cells has not been shown 
conclusively as yet.  
Adhesion of U937 monocytic cells to IL-1β-stimulated, but not to 
unstimulated HAEC was slightly increased only when both endothelial cells and 
monocytes were pretreated. The effect was shown to be mediated by VCAM-1 
and E-selectin 161. Wang et al. have shown that hyperhomocysteinemia stimulates 
the expression of VCAM-1 and E-Selectin in aortas of hyperhomocysteinemic 
mice, although the mechanisms had not been elucidated so far 195.  
Our data show – for the first time - that incubation of endothelial cells with 
pathophysiologically relevant concentrations of homocysteine lead to a time- and 
dose-dependent increase in the adhesion of monocytes to otherwise unstimulated 
endothelial cells (Figure 9). Monocyte adhesion was not stimulated by incubation 
of endothelial cells with cysteine, indicating that this effect does not seem to be an 
unspecific thiol effect. Furthermore, monocyte adhesion was only stimulated by 
incubation of endothelial cells with L-homocysteine, but not with D-homocysteine, 
demonstrating enantiomeric specificity for the naturally occurring stereoisomer 
(Figure 10).  
Mechanistically, increased binding of monocytes to homocysteine-
stimulated endothelial cells was mediated by increased de novo synthesis of 
ICAM-1 molecules on endothelial cells as shown by increased ICAM-1 expression 
using FACS analysis (Table 3) and increased ICAM-1 mRNA levels using real-
time RT-PCR. The functional role of increased ICAM-1 expression on monocyte 
adhesion to endothelial cells has been confirmed by blocking studies where a 
blocking antibody against ICAM-1 augmented homocysteine’s effect. NF-κB is a 
transcription factor that activates a variety of target genes relevant to the 
pathophysiology of the vessel wall, including cytokines, chemokines, and 
leukocyte adhesion molecules (including ICAM-1), as well as genes that regulate 
cell proliferation and mediate cell survival. Physiological modulation and 
pathological activation of the NF-κB system may contribute to the changes in gene 
70 
expression that occur during atherogenesis. Diverse stimuli activate NF-κB, 
through the phosphorylation and activation of the IκB kinase (IKK) complex. The 
experiments that we have performed indicated that incubation of EA.hy 926 cells 
only with homocysteine and not with other thiols resulted in significantly increased 
nuclear staining for the NF-κB p65 subunit, demonstrating increased nuclear 
translocation. An increased activation of NF-κB in aortas of mildly 
hyperhomocysteinemic rats compared to the control that was associated with an 
increased expression of ICAM-1 has recently been shown 196. This confirms the 
relevance of our findings for the in vivo situation.  
Support of the role of NF-κB in homocysteine-induced activation of 
endothelial cells is derived from inhibitor studies (Table 5, Figure 14) using Bay 
11-7082, which is known to block TNFα-induced endothelial-leukocyte cell 
adhesion via inhibiton of NF-κB translocation. Cotreatment of endothelial cells with 
homocysteine and Bay 11-7082 reduced the number of adherent monocytes and 
ICAM-1 expression to control levels. This shows that homocysteine modulates 
ICAM-1 expression on the surface of endothelial cells by an NF-κB dependent 
pathway and thereby triggers monocyte adhesion to endothelial monolayer.  
All these changes in endothelial and monocytic phenotypes occur only if 
cells are incubated with the L-stereoisomer of homocysteine which is taken up 
intracellularly, probably by a cysteine transporter, but do not occur when 
incubating the cells with the D-stereoismer. This indicates that the effects of 
homocysteine are mediated by intracellular events and not in the extracellular 
space. Furthermore, this indicates, that the effects of homocysteine are due to a 
biochemical, and not due to a simple chemical effect of homocysteine, as the D-
stereoismer of homocysteine may mediate the same chemical modifications of 
proteins and other targets as the L-stereosimer, but does not participate in 
biochemical reaction, like for example posttranslational modifications of proteins. 
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Incubation of THP-1 cells with D,L-homocysteine and L-homocysteine 
resulted in a significant increase in the number of adhering monocytes to 
unstimulated EA.hy 926 or HUVEC monolayers up to 3 fold at the highest 
concentration studied compared to control conditions. L-cysteine and D-
homocysteine, again, had no significant effect (Figure 17). In addition, LFA-1β, the 
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major ligand for the endothelial ICAM-1 on monocytes, was upregulated by 
homocysteine as well. These data were confirmed by increased surface 
expression determined by flow cytometry in THP-1 cells and blocking studies with 
an anti LFA-1β antibody (Figure 18). Both approaches significantly reduced 
homocysteine-induced monocytes adhesion to endothelial cells.  
Several studies suggest that the transcription factor NF-κB plays an 
important role in upregulating the expression of β2-integrins LFA-1β and Mac-1α 
and other inflammatory factors in atherosclerotic lesions. The promoter region of 
the β2-integrins LFA-1β and Mac-1α genes contains several putative binding sites 
for transcription-activator factors. 197 Wang and collaborators showed that 
homocysteine induces NF-κB translocation in THP-1-derived macrophages 163 
which correlates with high integrin expression on the surface of the monocytes. 
These complementary findings show that homocysteine not only has stimulatory 
effects on endothelial cells, but also on circulating monocytes. In addition, this 
shows that NF-κB translocation is required for these effects in both cases. 
 
Oxidant Stress Induced by Homocysteine in Endotheli al Cells and  
Monocytes 
 
Homocysteine is associated with increased vascular superoxide output 
and vascular oxidant stress. This effect is specific for homocysteine and does not 
occur with other low-molecular weight thiols, and is stereospecific for naturally 
occurring L-isoform of homocysteine 111. NF-κB is one of the transcription factors 
that may be controlled by the redox status of the cell 169. Indeed, generation of 
reactive oxygen species may be a common step in all of the signaling pathways 
that lead to IκB degradation and nuclear NF-κB accumulation. Support for this 
concept comes from a variety of studies showing that the diverse agents that can 
activate NF-κB also elevate levels of reactive oxygen species and that chemically 
distinct antioxidants, as well as overexpression of antioxidant enzymes, can inhibit 
NF-κB activation 198. However, a direct role of reactive oxygen species in signaling 
to NF-κB remains to be proven.  
Thus, for demonstrating the link between increased binding of monocytes, 
ICAM-1 expression, NF-κB translocation, and increased vascular oxidant stress 
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under conditions of elevated homocysteine levels, we have first monitored the 
intracellular generation of reactive oxygen species in homocysteine-incubated 
endothelial cells by loading them with the redox-sensitive dye DCF-DA, and 
second studied the effects of antioxidants on this signaling pathway and its 
functional consequences. Homocysteine-incubation resulted in a dose-dependent 
and significant increase in intracellular fluorescence indicative of increased 
generation of reactive oxygen species (Figure 12). The functional relevance of this 
redox-sensitive signaling pathway is confirmed by data that show that scavenging 
of reactive oxygen species by antioxidants like MnTBAP or Tiron abolished the 
homocysteine-induced endothelial ICAM-1 expression (Table 4), monocyte 
adhesion to endothelial cells (Figure 15), and NF-κB translocation (Figure 16).  
Significant superoxide release from homocysteine-incubated THP-1 cells 
further confirmed the hypothesis that homocysteine induces changes in cellular 
redox balance, even in non-endothelial cells.  
A potential source of reactive oxygen species in endothelial cells 
incubated with homocysteine may be endothelial nitric oxide synthase, as shown 
previously. 111 To test whether or not nitric oxide synthase may be a source of 
reactive oxygen species in non-endothelial cells as well, we treated THP-1 cells 
with L-NAME, which is an analog of L-arginine that inhibits nitric oxide production 
and superoxide production via NOS pathway 199. Inhibition of monocytic nitric 
oxide synthase attenuated the superoxide production (figure 20) and adhesion of 
monocytes (figure 21) induced by homocysteine. L-NMMA, another analogue of L-
arginine 199, which acts as a competitive inhibitor of all three isoforms of nitric 
oxide synthase (NOS), including inducible NOS (iNOS), and inhibits nitric oxide 
but not NOS-dependent superoxide production, did not show a significant effect 
on superoxide release (Figure 20) and adhesion of homocysteine-treated 
monocytes (Figure 21).  
One hypothesis that might explain why homocysteine induces NOS-
dependent superoxide production is that it depletes cellular stocks of 
tetrahydrobiopterin, leading to NOS-“uncoupling”. It has been shown that in this 
situation, NOS generates superoxide instead of nitric oxide. 120 Reasons for NOS-
“uncoupling” are reduced cellular availability of either the NOS-cofactor 
tetrahydrobiopterin or the NOS-substrate L-arginine. In these situations, the 
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electrons from heme reduce oxygen to form superoxide instead of reducing L-
arginine-derived nitrogen to form nitric oxide. L-sepiapterin is a synthetic precursor 
of tetrahydrobiopterin, which is converted to it intracellularly, and thereby 
stimulated NOS-cofactor availability. Incubation of THP-1 cells with sepiapterin 
decreased superoxide levels in homocysteine-treated cells (Figure 20) and 
inhibited monocyte arrest to endothelial cells (Figure 21). These results show that 
superoxide is generated in homocysteine-stimulated THP-1 cells at least partly by 
a NOS dependent pathway and that superoxide anion could enhance activation of 
monocytes and increased adhesion molecules expression by a redox sensitive 
pathway. 
In conclusion, these data indicate that increased vascular oxidant stress 
in hyperhomocysteinemia not only leads to a decrease in the bioavailability of 
nitric oxide derived from endothelial cells, but may also activate redox-sensitive 
signaling pathways in endothelial cells and circulating monocytes that induce a 
proinflammatory state in the vessel wall leading to increased adhesion molecule 
expression and monocyte recruitment (Figure 22). 
 
 
 
Figure 22: Hypothetic pathophysiological mechanism by which homocysteine induces 
vascular oxidant stress. 
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This may be an additional mechanism by which homocysteine promotes 
the development of atherosclerotic lesions.  
Strategies for defense against vascular oxidative stress and the resulting 
vascular damage that it generates may include treatment with antioxidants or 
overexpression of antioxidant enzymes, including catalase, several forms of 
superoxide dismutase, and glutathione peroxidase. Incorporation of antioxidants 
into vascular cells may reduce vascular cell oxidative stress. Some of these 
biologically relevant antioxidants have been shown to inhibit NF-κB activation in 
macrophages and cultured endothelial cells by decreasing oxidative stress 187,196, 
as in the study presented. By diminishing NF-κB activation, antioxidant vitamins, 
at least in part, may therefore diminish cellular responses to oxidized LDL, 
hyperhomocysteinemia, and other cardiovascular risk factors, leading to reduced 
monocyte adhesion, foam cell formation, and cytotoxicity to vascular cells, and 
finally improve vascular function. Taken together these findings are consistent with 
the concept that agents that diminish oxidant stress may stabilize the NF-κB 
system, and thereby may diminish the effect of homocysteine and other 
cardiovascular risk factors on the endothelium, which could lead to a decrease in 
atherosclerotic lesion formation. The information generated from these studies 
may thereby be helpful in designing intervention strategies aimed at inhibiting the 
generation of reactive oxygen species associated with cardiovascular risk factors, 
especially with hyperhomocysteinemia. This may have a favorable effect on 
signaling events involved in monocyte recruitment and infiltration during the 
formation of atherosclerotic lesions. 
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6. SUMMARY 
Mild hyperhomocysteinemia is an independent risk factor for the 
development of coronary artery disease, cerebrovascular disease and peripheral 
arterial disease. The mechanisms by which hyperhomocysteinemia promotes 
vascular disease are not completely understood yet. An increasing body of 
evidence has implicated oxidative stress as being contributory to homocysteine’s 
deleterious effects on the vasculature.  
Elevated levels of homocysteine lead to increased generation of 
superoxide anion in endothelial cells by a biochemical mechanism involving nitric 
oxide synthase, and, to a lesser extent, by an increase in the chemical oxidation 
rate of homocysteine and other aminothiols in the circulation. Furthermore, 
homocysteine has been shown to inhibit the activity of important cellular 
antioxidant enzymes, like the cellular isoform of glutathione peroxidase or 
superoxide dismutase, which may contribute to homocysteine’s induced oxidant 
stress. The resulting increase in reactive oxygen species leads to decreased 
bioavailability of the endothelium-derived signaling molecule nitric oxide via 
oxidative inactivation and thereby induces endothelial dysfunction. This seems to 
play a central role in the molecular mechanisms underlying the effects of 
homocysteine on vascular function. 
Hyperhomocysteinemia not only leads to endothelial dysfunction but also 
promotes the development and propagation of atherosclerotic lesion in 
atherosclerosis-prone animal models. As the recruitment of circulating monocytes 
to the vessel wall plays a crucial role in the process of atherosclerosis, the 
purpose of this study was to examine the influence of homocysteine on the 
interaction of endothelial cells with monocytes. 
Exposure of endothelial monolayers to D,L- and L-homocysteine resulted 
in a time- and dose-dependent increase in adherent THP-1 cells by upregulating 
ICAM-1 expression on endothelial cells. L-cysteine and D-homocysteine had no 
effects. This indicates that the stimulatory effect is specific for the naturally 
occurring L-stereoisomer and rather a biochemical than a chemical effect. The 
increased endothelial expression of ICAM-1 seems to be mediated by increased 
activation of the nuclear transcription factor NF-κB, as shown by increased nuclear 
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translocation of NF-κB in homocysteine-incubated endothelial cells. In 
accordance, inhibition of NF-κB translocation by a synthetic inhibitor Bay 11-7082 
significantly diminished homocysteine-induced ICAM-1 expression and adhesion 
of monocytes to endothelial cells.  
In addition, incubation of monocytes with D,L- homocysteine and L-
homocysteine resulted in significant increase in the number of adhering 
monocytes to unstimulated endothelial monolayer by upregulating the expression 
of β-2 integrins. 
Furthermore, homocysteine-incubation of endothelial cells and monocytes 
resulted in a dose-dependent and significant increase in the intracellular 
generation of reactive oxygen species. In support of the role of increased oxidant 
stress for the above mentioned effects, treatment of endothelial cells with the 
superoxide scavengers MnTBAP or Tiron together with homocysteine abolished 
homocysteine-induced monocyte adhesion, ICAM-1 expression and the nuclear 
translocation of NF-κB. Incubation of THP-1 monocytes with Tiron abolished 
homocysteine-induced β-2 integrin expression on these cells and adhesion to 
unstimulated endothelial cells. These findings suggest that superoxide anion 
radicals mediate homocysteine’s effects on endothelium-monocyte interactions.  
In addition to previous studies that indicated that a significant source of 
reactive oxygen species in homocysteine-treated endothelial cells might be 
endothelial nitric oxide synthase, experiments using inhibitors of nitric oxide 
synthase in THP-1 cells indicated that nitric oxide synthase-dependent generation 
of superoxide anion also occurs in homocysteine-incubated THP-1 cells. This 
mechanism may contribute to homocysteine-induced oxidant stress. 
The information generated from these studies may be helpful in designing 
intervention strategies aimed at inhibiting the generation of reactive oxygen 
species in the vasculature that is associated with signaling events of monocyte 
recruitment and infiltration involved in atherosclerosis. 
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7. ZUSAMMENFASSUNG 
Eine milde Hyperhomocysteinämie ist ein unabhängiger Risikofaktor für 
die Entwicklung von koronarer Herzerkrankung, zerebrovaskulärer Erkrankung 
oder peripherer arterieller Verschlusskrankheit. Die Mechanismen, über die eine 
Hyperhomocysteinämie vaskuläre Erkrankungen fördert, sind nicht vollständig 
verstanden. Experimentelle Daten weisen darauf hin, dass gesteigerter vaskulärer 
oxidativer Stress zu den nachteiligen Effekten von Homocystein (Hcy) auf die 
Gefäßwand wesentlich beträgt. 
Erhöhte Homocystein-Konzentrationen führen zu einer gesteigerten 
Bildung von Superoxidanion in Endothelzellen durch einen biochemischen 
Mechanismus, abhängig von endothelialer Stickstoffmonooxid-(NO)-Synthase, 
und, zu einem geringeren Ausmaß, durch chemische Oxidation von Homocystein 
und anderer Aminothiole in der Zirkulation. Zudem wurde gezeigt, dass 
Homocystein die Aktivität wichtiger zellulärer antioxidativer Enzyme hemmt, wie 
die zelluläre Isoform der Glutathion-Peroxidase oder die Superoxiddismutase. Der 
gesteigerte Anfall reaktiver Sauerstoffspezies verringert die Bioverfügbarkeit des 
vom Endothel gebildeten Signalmoleküls NO durch oxidative Inaktivierung und 
induziert eine endotheliale Dysfunktion. Dies scheint eine Schlüsselrolle in den 
molekularen Mechanismen zu spielen, die der Wirkung von Homocystein auf die 
Gefäßfunktion zugrunde liegen. 
Hyperhomocysteinämie führt nicht nur zu Endothelfunktionsstörung, 
sondern fördert auch die Entstehung und Progression atherosklerotischer 
Läsionen in hierfür empfänglichen Tiermodellen. Da die Rekrutierung 
zirkulierender Monozyten in die Gefäßwand eine Schlüsselrolle in der Entstehung 
atherosklerotischer Läsionen spielt, untersuchte diese Arbeit den Einfluss von 
Homocystein auf die Interaktion von Endothelzellen mit Monozyten. 
Die Inkubation von Endothelzellen mit D,L- und L-Hcy führte zu einer Zeit- 
und Dosis-abhängigen Zunahme der Adhäsion monozytärer THP-1 Zellen über 
eine Hochregulation der ICAM-1 Expression auf Endothelzellen. L-Cystein und D-
Hcy dagegen hatten keine Effekt. Dies zeigt, dass der stimulierende Effekt 
spezifisch für das natürlich vorkommende L-Stereoisomer ist, und eher durch 
einen biochemischen als einen chemischen Effekt verursacht wird. Die gesteigerte 
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endotheliale ICAM-1 Expression scheint über eine gesteigerte Aktivierung des 
nukleären Transkriptionsfaktors NF-κB vermittelt zu sein, wie durch eine 
gesteigerte nukleäre Translokation von NF-κB in Homocystein-inkubierten 
Endothelzellen gezeigt. In Übereinstimmung hiermit konnte die Hemmung der NF-
κB-Aktivierung mit dem synthetischen Inhibitor Bay 11-7082 die Hcy-induzierte 
ICAM-1 Expression und Monozyten-Adhäsion an Endothelzellen verringern.  
Zudem konnte gezeigt werden, dass die Inkubation von THP-1 
Monozyten mit D,L- und L-Homocystein zu einer signifikanten Zunahme der Zahl 
adhärenter Monozyten an unstimulierte Endothelzellen führt, vermittelt über eine 
Hochregulation der Expression von β-2-Integrinen. 
Homocystein-Inkubation von Endothelzellen und Monozyten führte zu 
einer Dosis-abhängigen und signifkanten Zunahme der intrazellulären Bildung 
reaktiver Sauerstoffspezies. Als Unterstützung für die Bedeutung der Rolle von 
gesteigertem oxidativen Stress für die beobachteten Effekte konnte gezeigt 
werden, dass die Behandlung von Endothelzellen mit den Superoxid-Scavengern 
MnTBAP oder Tiron zusammen mit Homocystein die Homocystein-induzierte 
Monozyten-Adhäsion, ICAM-1 Expression und nukleäre Translokation von NF-κB 
verhindert. Die Inkubation von THP-1 Monozyten mit Tiron verhindert die 
Homocystein-induzierte β-2-Integrin Expression auf diesen Zellen und die 
Adhäsion an unstimulierte Endothelzellen. Diese Beobachtungen lassen 
vermuten, dass Superoxidanion Radikale die Effekte von Homocystein auf die 
Interaktion von Endothelzellen mit Monozyten vermitteln. 
Frühere Studien zeigten, dass eine signifikante Quelle für reactive 
Sauerstoffspezies in Homocystein-inkubierten Endothelzellen die endotheliale NO 
Synthase darstellt. Experimente mit Inhibitoren der NO Synthase in THP-1 Zellen 
zeigen zudem, dass auch in diesem Zelltyp Homocystein zu einer NO Synthase-
abhängigen Bildung reaktiver Sauerstoffspezies führt. Dieser Mechanismus kann 
zu dem Homocystein-induzierten oxidativen Stress beitragen. 
Die Daten der vorgelegten Untersuchung können in Zukunft hilfreich sein, 
um Interventionsstudien zu planen, die darauf ausgerichtet sind, die vaskuläre 
Bildung reaktiver Sauerstoffspezies zu verringern. Hierdurch könnte die 
Signalkaskade, die zur Monozytenrekrutierung und –infiltration in die Gefäßwand 
im Prozess der Atheroskleroseentwicklung führt, beeinflusst werden.  
79 
8. REFERENCES 
 
1. Durrington P. Dyslipidaemia. Lancet. 2003;362:717-31. 
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 
2002;105:1135-43. 
3. Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, Topper JN, Annex 
BH, Rundback JH, Fabunmi RP, Robertson RM, Loscalzo J. Atherosclerotic vascular 
disease conference: Writing Group III: pathophysiology. Circulation. 2004;109:2617-25. 
4. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-26. 
5. Weiss N, Keller C, Hoffmann U, Loscalzo J. Endothelial dysfunction and atherothrombosis in 
mild hyperhomocysteinemia. Vasc Med. 2002;7:227-39. 
6. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. 
Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N 
Engl J Med. 1986;315:1046-51. 
7. Cox DA, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, Selwyn AP. 
Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation. 
1989;80:458-65. 
8. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in 
humans. Progressive endothelial dysfunction with different early stages of coronary 
atherosclerosis. Circulation. 1991;83:391-401. 
9. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon 
RO, 3rd. Nitric oxide activity in the human coronary circulation. Impact of risk factors for 
coronary atherosclerosis. J Clin Invest. 1995;95:1747-55. 
10. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, 
Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for 
coronary artery disease. Circulation. 1990;81:491-7. 
11. Nishimura RA, Lerman A, Chesebro JH, Ilstrup DM, Hodge DO, Higano ST, Holmes DR, Jr., 
Tajik AJ. Epicardial vasomotor responses to acetylcholine are not predicted by coronary 
atherosclerosis as assessed by intracoronary ultrasound. J Am Coll Cardiol. 1995;26:41-9. 
12. McLenachan JM, Williams JK, Fish RD, Ganz P, Selwyn AP. Loss of flow-mediated 
endothelium-dependent dilation occurs early in the development of atherosclerosis. 
Circulation. 1991;84:1273-8. 
13. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator 
dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 
2000;101:1899-906. 
14. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Jr., Lerman A. Long-term 
follow-up of patients with mild coronary artery disease and endothelial dysfunction. 
Circulation. 2000;101:948-54. 
80 
15. Guerra R, Jr., Brotherton AF, Goodwin PJ, Clark CR, Armstrong ML, Harrison DG. 
Mechanisms of abnormal endothelium-dependent vascular relaxation in atherosclerosis: 
implications for altered autocrine and paracrine functions of EDRF. Blood Vessels. 
1989;26:300-14. 
16. Luscher TF, Richard V, Tschudi M, Yang ZH, Boulanger C. Endothelial control of vascular 
tone in large and small coronary arteries. J Am Coll Cardiol. 1990;15:519-27. 
17. Cooke JP, Stamler J, Andon N, Davies PF, McKinley G, Loscalzo J. Flow stimulates 
endothelial cells to release a nitrovasodilator that is potentiated by reduced thiol. Am J 
Physiol. 1990;259:H804-12. 
18. Ignarro LJ, Harbison RG, Wood KS, Kadowitz PJ. Activation of purified soluble guanylate 
cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: 
stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther. 
1986;237:893-900. 
19. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide. 2001;5:88-97. 
20. Drexler H. Nitric oxide and coronary endothelial dysfunction in humans. Cardiovasc Res. 
1999;43:572-9. 
21. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol 
Renal Physiol. 2001;280:F193-206. 
22. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of 
arteriosclerosis. Am J Pathol. 1969;56:111-28. 
23. Mudd SH, Skoby F, Levy HL, Pettigrew LKD, Wilcken B, R.E. P, Andria G, Boers GH, 
Bromberg IL, Cerone R. The natural history of homocystinuria due to cystathionine beta-
synthase deficiency. Am J Hum Genet. 1985;37:1-31. 
24. Yap S, Boers GH, Wilcken B, Wilcken DE, Brenton DP, Lee PJ, Walter JH, Howard PM, 
Naughten ER. Vascular outcome in patients with homocystinuria due to cystathionine beta-
synthase deficiency treated chronically: a multicenter observational study. Arterioscler 
Thromb Vasc Biol. 2001;21:2080-5. 
25. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, 
Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, 
Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland 
FM, Tan KS, Higgins I, Garcon D, Andria G, et al. Plasma homocysteine as a risk factor for 
vascular disease. The European Concerted Action Project. JAMA. 1997;277:1775-81. 
26. Kang SS, Wong PWK, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for  occlusive 
vascular disease. Annu Rev Nutr. 1992;12:279-98. 
27. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessement of 
plasma homocysteine as a risk factor for vascular disease. JAMA. 1995;274:1049-1057. 
28. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total 
homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704-9. 
81 
29. A'Brook R, Tavendale R, Tunstall-Pedoe H. Homocysteine and coronary risk in the general 
population: analysis from the Scottish Heart Health Study and Scottish MONICA surveys. 
Eur Heart J. 1998;19 (Suppl):8 (Abstr). 
30. Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, Jacques PF, 
Wilson PW. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular 
disease mortality in elderly Framingham men and women. Arch Intern Med. 1999;159:1077-
80. 
31. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, Koudstaal PJ, 
Grobbee DE. Homocysteine and short-term risk of myocardial infarction and stroke in the 
elderly: the Rotterdam Study. Arch Intern Med. 1999;159:38-44. 
32. Kark JD, Selhub J, Adler B, Gofin J, Abramson JH, Friedman G, Rosenberg IH. Nonfasting 
plasma total homocysteine level and mortality in middle-aged and elderly men and women in 
Jerusalem. Ann Intern Med. 1999;131:321-30. 
33. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis 
VW. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in 
end-stage renal disease. Circulation. 1998;97:138-41. 
34. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma 
homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 
1997;337:230-16. 
35. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of 
serum total homocysteine concentration and risk of stroke in middle-aged British men. 
Lancet. 1995;346:1395-8. 
36. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma 
homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. 
Lancet. 1996;348:1120-24. 
37. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocysteine and 
risk of cardiovascular disease among postmenopausal women. JAMA. 1999;281:1817-21. 
38. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, 
Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial 
infarction in US physicians. Jama. 1992;268:877-81. 
39. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic 
heart disease: results of a prospective study with implications regarding prevention. Arch 
Intern Med. 1998;158:862-7. 
40. Whincup PH, Refsum H, Perry IJ, Morris R, Walker M, Lennon L, Thomson A, Ueland PM, 
Ebrahim SB. Serum total homocysteine and coronary heart disease: prospective study in 
middle aged men. Heart. 1999;82:448-54. 
41. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, Salonen JT, 
Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to 
atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 
1994;106:9-19. 
82 
42. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk of 
cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb 
Vasc Biol. 1997;17:1947-53. 
43. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, Hess DL, Davis 
CE. Prospective study of coronary heart disease incidence in relation to fasting total 
homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in 
Communities (ARIC) study. Circulation. 1998;98:204-10. 
44. Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation. 
1998;98:196-9. 
45. Ubbink JB, Fehily AM, Pickering J, Elwood PC, Vermaak WJ. Homocysteine and ischaemic 
heart disease in the Caerphilly cohort. Atherosclerosis. 1998;140:349-56. 
46. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective 
study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 1994;25:1924-30. 
47. Weiss N, Hilge R, Hoffmann U. Mild hyperhomocysteinemia: Risk factor or just risk predictor 
for cardiovascular diseases. VASA. 2004;33:191-203. 
48. Hopkins PN, Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams RR. Higher plasma 
homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial 
coronary artery disease. Arterioscler Thromb Vasc Biol. 1995;15:1314-20. 
49. Pancharuniti N, Lewis CA, Sauberlich HE, Perkins LL, Go RC, Alvarez JO, Macaluso M, 
Acton RT, Copeland RB, Cousins AL, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 
concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr. 
1994;59:940-8. 
50. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic 
review of published epidemiological studies. J Cardiovasc Risk. 1998;5:229-32. 
51. Moller J, Nielsen GM, Tvedegaard KC, Andersen NT, Jorgensen PE. A meta-analysis of 
cerebrovascular disease and hyperhomocysteinaemia. Scand J Clin Lab Invest. 
2000;60:491-9. 
52. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and 
cardiovascular risk. Am J Clin Nutr. 2000;72:324-32. 
53. Schnyder G, Pin R, Roffi M, Flammer Y, Hess OM. Association of plasma homocysteine with 
the number of major coronary arteries severely narrowed. Am J Cardiol. 2001;88:1027-30. 
54. Alfthan G, Aro A, Gey KF. Plasma homocysteine and cardiovascular disease mortality. 
Lancet. 1997;349:397. 
55. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, Pearson RR. 
Plasma homocysteine predicts mortality independently of traditional risk factors and C-
reactive protein in patients with angiographically defined coronary artery disease. 
Circulation. 2000;102:1227-32. 
56. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and 
increased risks of cardiovascular disease: causal or casual? Arch Intern Med. 2000;160:422-
34. 
83 
57. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, 
Stehouwer CD. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes 
: 5-year follow-up of the Hoorn Study. Circulation. 2000;101:1506-11. 
58. Stehouwer CD, Gall MA, Hougaard P, Jakobs C, Parving HH. Plasma homocysteine 
concentration predicts mortality in non-insulin-dependent diabetic patients with and without 
albuminuria. Kidney Int. 1999;55:308-14. 
59. Taylor LM, Jr., Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of 
the relationship between plasma homocysteine and progression of symptomatic peripheral 
arterial disease. J Vasc Surg. 1999;29:8-19. 
60. Chao CL, Tsai HH, Lee CM, Hsu SM, Kao JT, Chien KL, Sung FC, Lee YT. The graded 
effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. 
Atherosclerosis. 1999;147:379-86. 
61. van den Berg M, Stehouwer CD, Bierdrager E, Rauwerda JA. Plasma homocysteine and 
severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. 
Arterioscler Thromb Vasc Biol. 1996;16:165-71. 
62. Verhoef P, Kok FJ, Kruyssen DA, Schouten EG, Witteman JC, Grobbee DE, Ueland PM, 
Refsum H. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. 
Arterioscler Thromb Vasc Biol. 1997;17:989-95. 
63. von Eckardstein A, Malinow MR, Upson B, Heinrich J, Schulte H, Schonfeld R, Kohler E, 
Assmann G. Effects of age, lipoproteins, and hemostatic parameters on the role of 
homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb. 
1994;14:460-4. 
64. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall 
thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in 
Communities Study. Circulation. 1993;87:1107-13. 
65. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, O'Leary DH, 
Wolf PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine 
concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286-91. 
66. Willinek WA, Ludwig M, Lennarz M, Holler T, Stumpe KO. High-normal serum homocysteine 
concentrations are associated with an increased risk of early atherosclerotic carotid artery 
wall lesions in healthy subjects. J Hypertens. 2000;18:425-30. 
67. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Bones C, Newcombe RG, Lewis MJ. 
Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in 
healthy adults. Circulation. 1998;98:1848-52. 
68. Hanratty CG, McAuley DF, McGurk C, Young IS, Johnston GD. Homocysteine and 
endothelial vascular function. Lancet. 1998;351:1288-9. 
69. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid 
onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with 
vitamin C therapy. Circulation. 1999;99:1156-60. 
84 
70. Chambers JC, Obeid OA, Kooner JS. Physiological increments in plasma homocysteine 
induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb Vasc 
Biol. 1999;19:2922-7. 
71. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant 
stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in 
humans. Circulation. 1999;100:1161-8. 
72. Lambert J, van den Berg M, Steyn M, Rauwerda JA, Donker AJ, Stehouwer CD. Familial 
hyperhomocysteinaemia and endothelium-dependent vasodilatation and arterial distensibility 
of large arteries. Cardiovasc Res. 1999;42:743-51. 
73. Chao CL, Kuo TL, Lee YT. Effects of methionine-induced hyperhomocysteinemia on 
endothelium-dependent vasodilation and oxidative status in healthy adults. Circulation. 
2000;101:485-90. 
74. Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, Haynes WG. Elevation of asymmetrical 
dimethylarginine may mediate endothelial dysfunction during experimental 
hyperhomocyst(e)inaemia in humans. Clin Sci (Lond). 2001;100:161-7. 
75. Chambers JC, Ueland PM, Wright M, Dore CJ, Refsum H, Kooner JS. Investigation of 
relationship between reduced, oxidized, and protein-bound homocysteine and vascular 
endothelial function in healthy human subjects. Circ Res. 2001;89:187-92. 
76. Hanratty CG, McGrath LT, McAuley DF, Young IS, Johnston GD. The effects of oral 
methionine and homocysteine on endothelial function. Heart. 2001;85:326-330. 
77. Raghuveer G, Sinkey CA, Chenard C, Stumbo P, Haynes WG. Effect of vitamin E on 
resistance vessel endothelial dysfunction induced by methionine. Am J Cardiol. 
2001;88:285-90. 
78. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, 
Celermajer DS. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in 
humans. Circulation. 1997;96:2542-4. 
79. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is 
associated with impaired endothelium- dependent vasodilation in humans. Circulation. 
1997;95:1119-21. 
80. Holven KB, Holm T, Aukrust P, Christensen B, Kjekshus J, Andreassen AK, Gullestad L, 
Hagve TA, Svilaas A, Ose L, Nenseter MS. Effect of folic acid treatment on endothelium-
dependent vasodilation and nitric oxide-derived end products in hyperhomocysteinemic 
subjects. Am J Med. 2001;110:536-42. 
81. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Newcombe RG, Lewis MJ. Oral folate 
enhances endothelial function in hyperhomocysteinaemic subjects. Eur J Clin Invest. 
1999;29:659-62. 
82. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves 
arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol. 
1999;34:2002-6. 
85 
83. Chao CL, Chien KL, Lee YT. Effect of short-term vitamin (folic acid, vitamins B6 and B12) 
administration on endothelial dysfunction induced by post-methionine load 
hyperhomocysteinemia. Am J Cardiol. 1999;84:1359-61. 
84. Title LM, Cummings PM, Giddens K, Genest JJ, Jr., Nassar BA. Effect of folic acid and 
antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J 
Am Coll Cardiol. 2000;36:758-65. 
85. Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS. Improved vascular 
endothelial function after oral B vitamins: An effect mediated through reduced concentrations 
of free plasma homocysteine. Circulation. 2000;102:2479-83. 
86. Doshi SN, McDowell IF, Moat SJ, Lang D, Newcombe RG, Kredan MB, Lewis MJ, 
Goodfellow J. Folate improves endothelial function in coronary artery disease: an effect 
mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol. 
2001;21:1196-202. 
87. Doshi SN, McDowell IF, Moat SJ, Payne N, Durrant HJ, Lewis MJ, Goodfellow J. Folic acid 
improves endothelial function in coronary artery disease via mechanisms largely 
independent of homocysteine lowering. Circulation. 2002;105:22-6. 
88. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as 
primary determinants of homocysteinemia in an elderly population. JAMA. 1993;124:1927-
33. 
89. Ubbink JB. The role of vitamins in the pathogenesis and treatment of 
hyperhomocyst(e)inaemia. J Inherit Metab Dis. 1997;20:316-25. 
90. Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: review of the 
randomized trials of homocysteine-lowering vitamin supplements. Semin Thromb Hemost. 
2000;26:341-48. 
91. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-
50. 
92. Weiss N, Heydrick SJ, Postea O, Keller C, Keaney JF, Jr., Loscalzo J. Influence of 
hyperhomocysteinemia on the cellular redox state - impact on homocysteine-induced 
endothelial dysfunction. Clin Chem Lab Med. 2003;41:1455-61. 
93. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD. 
Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 
1996;98:24-9. 
94. Ungvari Z, Pacher P, Rischak K, Szollar L, Koller A. Dysfunction of nitric oxide mediation in 
isolated rat arterioles with methionine diet-induced hyperhomocysteinemia. Arterioscler 
Thromb Vasc Biol. 1999;19:1899-904. 
95. Bagi Z, Ungvari Z, Szollar L, Koller A. Flow-induced constriction in arterioles of 
hyperhomocysteinemic rats is due to impaired nitric oxide and enhanced thromboxane A(2) 
mediation. Arterioscler Thromb Vasc Biol. 2001;21:233-7. 
96. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Stark R, 
Klings ES, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, 
86 
Loscalzo J. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J 
Clin Invest. 2000;106:483-91. 
97. Weiss N, Zhang YY, Heydrick S, Bierl C, Loscalzo J. Overexpression of cellular glutathione 
peroxidase rescues homocyst(e)ine-induced endothelial dysfunction. Proc Natl Acad Sci U S 
A. 2001;98:12503-8. 
98. Weiss N, Heydrick S, Zhang YY, Bierl C, Cap A, Loscalzo J. Cellular redox state and 
endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase-
deficient mice. Arterioscler Thromb Vasc Biol. 2002;22:34-41. 
99. Lentz SR, Erger RA, Dayal S, Maeda N, Malinow MR, Heistad DD, Faraci FM. Folate 
dependence of hyperhomocysteinemia and vascular dysfunction in cystathionine beta-
synthase-deficient mice. Am J Physiol Heart Circ Physiol. 2000;279:H970-5. 
100. Upchurch GR, Jr., Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF, Jr., 
Loscalzo J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving 
glutathione peroxidase. J Biol Chem. 1997;272:17012-7. 
101. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS. Effects of homocysteine on 
endothelial nitric oxide production. Am J Physiol Renal Physiol. 2000;279:F671-8. 
102. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest. 1996;98:5-7. 
103. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of 
endothelium-derived vascular relaxing factor. Nature. 1986;320:454-6. 
104. Rubbo H, Freeman BA. Nitric oxide regulation of lipid oxidation reactions: formation and 
analysis of nitrogen-containing oxidized lipid derivatives. Methods Enzymol. 1996;269:385-
94. 
105. Mujumdar VS, Aru GM, Tyagi SC. Induction of oxidative stress by homocyst(e)ine impairs 
endothelial function. J Cell Biochem. 2001;82:491-500. 
106. Lang D, Kredan MB, Moat SJ, Hussain SA, Powell CA, Bellamy MF, Powers HJ, Lewis MJ. 
Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for 
superoxide anions. Arterioscler Thromb Vasc Biol. 2000;20:422-7. 
107. Zhang F, Slungaard A, Vercellotti GM, Iadecola C. Superoxide-dependent cerebrovascular 
effects of homocysteine. Am J Physiol. 1998;274:R1704-11. 
108. Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G. Peroxidation indices and total 
antioxidant capacity in plasma during hyperhomocysteinemia induced by methionine oral 
loading. Metabolism. 2000;49:225-8. 
109. Voutilainen S, Morrow JD, Roberts LJ, 2nd, Alfthan G, Alho H, Nyyssonen K, Salonen JT. 
Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. 
Arterioscler Thromb Vasc Biol. 1999;19:1263-6. 
110. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in 
superoxide production and modification of low density lipoprotein by arterial smooth muscle 
cells. J Biol Chem. 1987;262:10098-103. 
87 
111. Heydrick SJ, Weiss N, Thomas SR, Cap AP, Pimentel DR, Loscalzo J, Keaney JF, Jr. L-
homocysteine and L-homocystine stereospecifically induce endothelial nitric oxide synthase-
dependent lipid peroxidation in endothelial cells. Free Radic Biol Med. 2004;36:632-40. 
112. Nishio E, Watanabe Y. Homocysteine as a modulator of platelet-derived growth factor action 
in vascular smooth muscle cells: a possible role for hydrogen peroxide. Br J Pharmacol. 
1997;122:269-74. 
113. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an 
inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992;20:S60-2. 
114. McDermott JR. Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine 
and Ng, Ng-dimethylarginine in the rabbit. Biochem J. 1976;154:179-84. 
115. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of 
asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in 
monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc 
Biol. 2000;20:1557-64. 
116. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the 
nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 
2001;104:2569-75. 
117. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for 
endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. 
Circulation. 1999;99:3092-5. 
118. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid 
peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys. 
1991;288:481-7. 
119. Possel H, Noack H, Augustin W, Keilhoff G, Wolf G. 2,7-Dihydrodichlorofluorescein 
diacetate as a fluorescent marker for peroxynitrite formation. FEBS Lett. 1997;416:175-8. 
120. Topal G, Brunet A, Millanvoye E, Boucher JL, Rendu F, Devynck MA, David-Dufilho M. 
Homocysteine induces oxidative stress by uncoupling of no synthase activity through 
reduction of tetrahydrobiopterin. Free Radic Biol Med. 2004;36:1532-41. 
121. Mansoor MA, Svardal AM, Schneede J, Ueland PM. Dynamic relation between reduced, 
oxidized, and protein-bound homocysteine and other thiol components in plasma during 
methionine loading in healthy men. Clin Chem. 1992;38:1316-21. 
122. Mansoor MA, Guttormsen AB, Fiskerstrand T, Refsum H, Ueland PM, Svardal AM. Redox 
status and protein binding of plasma aminothiols during the transient hyperhomocysteinemia 
that follows homocysteine administration. Clin Chem. 1993;39:980-5. 
123. Guttormsen AB, Mansoor AM, Fiskerstrand T, Ueland PM, Refsum H. Kinetics of plasma 
homocysteine in healthy subjects after peroral homocysteine loading. Clin Chem. 
1993;39:1390-7. 
124. Andersson A, Lindgren A, Hultberg B. Effect of thiol oxidation and thiol export from 
erythrocytes on determination of redox status of homocysteine and other thiols in plasma 
from healthy subjects and patients with cerebral infarction. Clin Chem. 1995;41:361-6. 
88 
125. Mansoor MA, Bergmark C, Svardal AM, Lonning PE, Ueland PM. Redox status and protein 
binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral 
vascular disease. Homocysteine and peripheral vascular disease. Arterioscler Thromb Vasc 
Biol. 1995;15:232-40. 
126. Mansoor MA, Ueland PM, Svardal AM. Redox status and protein binding of plasma 
homocysteine and other aminothiols in patients with hyperhomocysteinemia due to 
cobalamin deficiency. Am J Clin Nutr. 1994;59:631-5. 
127. Mansoor MA, Ueland PM, Aarsland A, Svardal AM. Redox status and protein binding of 
plasma homocysteine and other aminothiols in patients with homocystinuria. Metabolism. 
1993;42:1481-5. 
128. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, Jacobsen DW. Relative roles 
of albumin and ceruloplasmin in the formation of homocystine, homocysteine-cysteine-mixed 
disulfide, and cystine in circulation. J Biol Chem. 2001;276:46896-904. 
129. Outinen PA, Sood SK, Pfeifer SI, Pamidi S, Podor TJ, Li J, Weitz JI, Austin RC. 
Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific 
changes in gene expression in human vascular endothelial cells. Blood. 1999;94:959-67. 
130. Weiss N, Zhang Y, Loscalzo J. Homocyst(e)ine impairs cellular glutathione peroxidase 
expression and promotes endothelial dysfunction in an animal model of 
hyperhomocyst(e)inemia. Circulation. 2000;102:II-238. 
131. Flohé L. The selenoprotein glutathione peroxidase. In: Dolphin D, Poulson R, Avramovic O, 
eds. Glutathione: chemical, biochemical and medical aspects: John Wiley & Sons, Inc.; 
1989:644-731. 
132. Sies H, Sharov VS, Klotz LO, Briviba K. Glutathione peroxidase protects against 
peroxynitrite-mediated oxidations. A new function for selenoproteins as peroxynitrite 
reductase. J Biol Chem. 1997;272:27812-7. 
133. O'Donnell VB, Freeman BA. Interactions between nitric oxide and lipid oxidation pathways: 
implications for vascular disease. Circ Res. 2001;88:12-21. 
134. Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B, Barnes S, Kirk M, Freeman BA. 
Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. 
Formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem. 
1994;269:26066-75. 
135. Karlsson K, Marklund SL. Heparin-induced release of extracellular superoxide dismutase to 
human blood plasma. Biochem J. 1987;242:55-9. 
136. Adachi T, Yamada H, Futenma A, Kato K, Hirano K. Heparin-induced release of 
extracellular-superoxide dismutase form (V) to plasma. J Biochem (Tokyo). 1995;117:586-
90. 
137. Wilcken DE, Wang XL, Adachi T, Hara H, Duarte N, Green K, Wilcken B. Relationship 
between homocysteine and superoxide dismutase in homocystinuria: possible relevance to 
cardiovascular risk. Arterioscler Thromb Vasc Biol. 2000;20:1199-202. 
89 
138. Wang XL, Duarte N, Cai H, Adachi T, Sim AS, Cranney G, Wilcken DE. Relationship 
between total plasma homocysteine, polymorphisms of homocysteine metabolism related 
enzymes, risk factors and coronary artery disease in the Australian hospital-based 
population. Atherosclerosis. 1999;146:133-40. 
139. Yamamoto M, Hara H, Adachi T. Effects of homocysteine on the binding of extracellular-
superoxide dismutase to the endothelial cell surface. FEBS Lett. 2000;486:159-62. 
140. Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen DW. Homocysteine 
induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in 
human aortic endothelial cells: implications for vascular disease. Circulation. 2001;103:2717-
23. 
141. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ, Jr., Kohl B, Rao V, 
Kisiel W, Stern DM, Schmidt AM. Hyperhomocysteinemia enhances vascular inflammation 
and accelerates atherosclerosis in a murine model. J Clin Invest. 2001;107:675-83. 
142. Zhang C, Cai Y, Adachi MT, Oshiro S, Aso T, Kaufman RJ, Kitajima S. Homocysteine 
induces programmed cell death in human vascular endothelial cells through activation of the 
unfolded protein response. J Biol Chem. 2001;276:35867-74. 
143. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME. Promotion of 
vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl 
Acad Sci U S A. 1994;91:6369-73. 
144. Chen JZ, Zhu JH, Wang XX, Xie XD, Sun J, Shang YP, Guo XG, Dai HM, Hu SJ. Effects of 
homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J 
Mol Cell Cardiol. 2004;36:233-9. 
145. Suhara T, Fukuo K, Yasuda O, Tsubakimoto M, Takemura Y, Kawamoto H, Yokoi T, Mogi 
M, Kaimoto T, Ogihara T. Homocysteine enhances endothelial apoptosis via upregulation of 
Fas-mediated pathways. Hypertension. 2004;43:1208-13. 
146. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse 
vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and 
related oxides of nitrogen. J Clin Invest. 1993;91:308-18. 
147. Graeber JE, Slott JH, Ulane RE, Schulman JD, Stuart MJ. Effect of homocysteine and 
homocystine on platelet and vascular arachidonic acid metabolism. Pediatr Res. 
1982;16:490-3. 
148. Panganamala RV, Karpen CW, Merola AJ. Peroxide mediated effects of homocysteine on 
arterial prostacyclin synthesis. Prostaglandins Leukot Med. 1986;22:349-56. 
149. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor 
for premature vascular disease and thrombosis, induces tissue factor activity in endothelial 
cells. Arterioscler Thromb. 1993;13:1327-33. 
150. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced 
vascular endothelial cell activator. J Clin Invest. 1986;77:1909-16. 
90 
151. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses 
anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin 
Invest. 1993;92:1381-6. 
152. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its 
endothelial cell membrane receptor. J Clin Invest. 1993;91:2873-9. 
153. Hajjar KA, Mauri L, Jacovina AT, Zhong F, Mirza UA, Padovan JC, Chait BT. Tissue 
plasminogen activator binding to the annexin II tail domain. Direct modulation by 
homocysteine. J Biol Chem. 1998;273:9987-93. 
154. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C 
activation by arterial and venous endothelial cells. Blood. 1990;75:895-901. 
155. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced 
hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and 
macrophage-derived tissue factor activity in rats. Faseb J. 1997;11:1157-68. 
156. Constans J, Blann AD, Resplandy F, Parrot F, Seigneur M, Renard M, Amiral J, Guerin V, 
Boisseau MR, Conri C. Endothelial dysfunction during acute methionine load in 
hyperhomocysteinaemic patients. Atherosclerosis. 1999;147:411-3. 
157. Beauchamp MC, Renier G. Homocysteine induces protein kinase C activation and 
stimulates c-Fos and lipoprotein lipase expression in macrophages. Diabetes. 
2002;51:1180-7. 
158. Maeda M, Yamamoto I, Fujio Y, Azuma J. Homocysteine induces vascular endothelial 
growth factor expression in differentiated THP-1 macrophages. Biochim Biophys Acta. 
2003;1623:41-6. 
159. Alvarez-Maqueda M, El Bekay R, Monteseirin J, Alba G, Chacon P, Vega A, Santa Maria C, 
Tejedo JR, Martin-Nieto J, Bedoya FJ, Pintado E, Sobrino F. Homocysteine enhances 
superoxide anion release and NADPH oxidase assembly by human neutrophils. Effects on 
MAPK activation and neutrophil migration. Atherosclerosis. 2004;172:229-38. 
160. Song YS, Rosenfeld ME. Methionine-induced hyperhomocysteinemia promotes superoxide 
anion generation and NFkappaB activation in peritoneal macrophages of C57BL/6 mice. J 
Med Food. 2004;7:229-34. 
161. Koga T, Claycombe K, Meydani M. Homocysteine increases monocyte and T-cell adhesion 
to human aortic endothelial cells. Atherosclerosis. 2002;161:365-74. 
162. Wang G, Siow YL, O K. Homocysteine stimulates nuclear factor kappaB activity and 
monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells: a possible 
role for protein kinase C. Biochem J. 2000;352:817-26. 
163. Wang G, Siow YL, O K. Homocysteine induces monocyte chemoattractant protein-1 
expression by activating NF-kappaB in THP-1 macrophages. Am J Physiol Heart Circ 
Physiol. 2001;280:H2840-7. 
164. Wang G, O K. Homocysteine stimulates the expression of monocyte chemoattractant 
protein-1 receptor (CCR2) in human monocytes: possible involvement of oxygen free 
radicals. Biochem J. 2001;357:233-40. 
91 
165. Xie QW, Whisnant R, Nathan C. Promoter of the mouse gene encoding calcium-
independent nitric oxide synthase confers inducibility by interferon gamma and bacterial 
lipopolysaccharide. J Exp Med. 1993;177:1779-84. 
166. Kim YM, Lee BS, Yi KY, Paik SG. Upstream NF-kappaB site is required for the maximal 
expression of mouse inducible nitric oxide synthase gene in interferon-gamma plus 
lipopolysaccharide-induced RAW 264.7 macrophages. Biochem Biophys Res Commun. 
1997;236:655-60. 
167. Cardozo AK, Heimberg H, Heremans Y, Leeman R, Kutlu B, Kruhoffer M, Orntoft T, Eizirik 
DL. A comprehensive analysis of cytokine-induced and nuclear factor-kappa B-dependent 
genes in primary rat pancreatic beta-cells. J Biol Chem. 2001;276:48879-86. Epub 2001 Oct 
30. 
168. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, 
Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in 
the atherosclerotic lesion. J Clin Invest. 1996;97:1715-22. 
169. Ogata N, Yamamoto H, Kugiyama K, Yasue H, Miyamoto E. Involvement of protein kinase C 
in superoxide anion-induced activation of nuclear factor-kappa B in human endothelial cells. 
Cardiovasc Res. 2000;45:513-21. 
170. Zeng X, Dai J, Remick DG, Wang X. Homocysteine mediated expression and secretion of 
monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. Circ Res. 
2003;93:311-20. 
171. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures. Possible 
mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem. 
1997;272:1935-42. 
172. Jakubowski H. Protein N-homocysteinylation: implications for atherosclerosis. Biomed 
Pharmacother. 2001;55:443-7. 
173. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, Gerritsen ME. Novel 
inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion 
molecule expression show anti-inflammatory effects in vivo. J Biol Chem. 1997;272:21096-
103. 
174. Edgell CJ, McDonald CC, Graham JB. Permanent cell line expressing human factor VIII-
related antigen established by hybridization. Proc Natl Acad Sci U S A. 1983;80:3734-7. 
175. Mutin M, Dignat-George F, Sampol J. Immunologic phenotype of cultured endothelial cells: 
quantitative analysis of cell surface molecules. Tissue Antigens. 1997;50:449-58. 
176. Dwivedi A, Anggard EE, Carrier MJ. Oxidized LDL-mediated monocyte adhesion to 
endothelial cells does not involve NFkappaB. Biochem Biophys Res Commun. 
2001;284:239-44. 
177. Claise C, Edeas M, Chaouchi N, Chalas J, Capel L, Kalimouttou S, Vazquez A, Lindenbaum 
A. Oxidized-LDL induce apoptosis in HUVEC but not in the endothelial cell line EA.hy 926. 
Atherosclerosis. 1999;147:95-104. 
92 
178. Krotz F, Sohn HY, Keller M, Gloe T, Bolz SS, Becker BF, Pohl U. Depolarization of 
endothelial cells enhances platelet aggregation through oxidative inactivation of endothelial 
NTPDase. Arterioscler Thromb Vasc Biol. 2002;22:2003-9. 
179. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and 
characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer. 
1980;26:171-6. 
180. Stangl V, Gunther C, Jarrin A, Bramlage P, Moobed M, Staudt A, Baumann G, Stangl K, 
Felix SB. Homocysteine inhibits TNF-alpha-induced endothelial adhesion molecule 
expression and monocyte adhesion via nuclear factor-kappaB dependent pathway. Biochem 
Biophys Res Commun. 2001;280:1093-100. 
181. Berendt AR, McDowall A, Craig AG, Bates PA, Sternberg MJ, Marsh K, Newbold CI, Hogg 
N. The binding site on ICAM-1 for Plasmodium falciparum-infected erythrocytes overlaps, 
but is distinct from, the LFA-1-binding site. Cell. 1992;68:71-81. 
182. Sohn HY, Krotz F, Zahler S, Gloe T, Keller M, Theisen K, Schiele TM, Klauss V, Pohl U. 
Crucial role of local peroxynitrite formation in neutrophil-induced endothelial cell activation. 
Cardiovasc Res. 2003;57:804-15. 
183. Cathcart R, Schwiers E, Ames BN. Detection of picomole levels of hydroperoxides using a 
fluorescent dichlorofluorescein assay. Anal Biochem. 1983;134:111-6. 
184. Krotz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM, Becker BF, Theisen K, Klauss 
V, Pohl U. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet 
recruitment. Blood. 2002;100:917-24. 
185. Yin JL, Shackel NA, Zekry A, McGuinness PH, Richards C, Putten KV, McCaughan GW, 
Eris JM, Bishop GA. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) 
for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or 
SYBR Green I. Immunol Cell Biol. 2001;79:213-21. 
186. Henger A, Kretzler M, Doran P, Bonrouhi M, Schmid H, Kiss E, Cohen CD, Madden S, 
Porubsky S, Grone EF, Schlondorff D, Nelson PJ, Grone HJ. Gene expression fingerprints in 
human tubulointerstitial inflammation and fibrosis as prognostic markers of disease 
progression. Kidney Int. 2004;65:904-917. 
187. Zahler S, Kupatt C, Becker BF. Endothelial preconditioning by transient oxidative stress 
reduces inflammatory responses of cultured endothelial cells to TNF-alpha. Faseb J. 
2000;14:555-64. 
188. Au-Yeung KK, Woo CW, Sung FL, Yip JC, Siow YL, O K. Hyperhomocysteinemia activates 
nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res. 2004;94:28-36. 
189. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol. 
2003;91:3A-6A. 
190. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of 
endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976;58:731-41. 
93 
191. Zhou J, Moller J, Danielsen CC, Bentzon J, Ravn HB, Austin RC, Falk E. Dietary 
supplementation with methionine and homocysteine promotes early atherosclerosis but not 
plaque rupture in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:1470-6. 
192. Wang H, Jiang X, Yang F, Gaubatz JW, Ma L, Magera MJ, Yang X, Berger PB, Durante W, 
Pownall HJ, Schafer AI. Hyperhomocysteinemia accelerates atherosclerosis in cystathionine 
beta-synthase and apolipoprotein E double knock-out mice with and without dietary 
perturbation. Blood. 2003;101:3901-7. 
193. Sung FL, Slow YL, Wang G, Lynn EG, O K. Homocysteine stimulates the expression of 
monocyte chemoattractant protein-1 in endothelial cells leading to enhanced monocyte 
chemotaxis. Mol Cell Biochem. 2001;216:121-8. 
194. Dudman NP, Temple SE, Guo XW, Fu W, Perry MA. Homocysteine enhances neutrophil-
endothelial interactions in both cultured human cells and rats In vivo. Circ Res. 1999;84:409-
16. 
195. Wang G, Woo CW, Sung FL, Siow YL, O K. Increased monocyte adhesion to aortic 
endothelium in rats with hyperhomocysteinemia: role of chemokine and adhesion molecules. 
Arterioscler Thromb Vasc Biol. 2002;22:1777-83. 
196. Zhang R, Ma J, Xia M, Zhu H, Ling W. Mild hyperhomocysteinemia induced by feeding rats 
diets rich in methionine or deficient in folate promotes early atherosclerotic inflammatory 
processes. J Nutr. 2004;134:825-30. 
197. Hashizume K, Hatanaka Y, Fukuda I, Sano T, Yamaguchi Y, Tani Y, Danno G, Suzuki K, 
Ashida H. N-acetyl-L-cysteine suppresses constitutive expression of CD11a/LFA-1alpha 
protein in myeloid lineage. Leuk Res. 2002;26:939-44. 
198. Haddad JJ. Oxygen sensing and oxidant/redox-related pathways. Biochem Biophys Res 
Commun. 2004;316:969-77. 
199. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three 
inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol. 
1990;101:746-52. 
 
 
 
 
 
 
 
 
 
94 
ACKNOWLEDGMENTS 
I would like to thank: 
 
Priv. Doz. Dr. med. Norbert Weiss and Dr. med. Florian Krötz for the great 
scientific support in performing this project  
 
Prof. Christiane Keller for offering me the chance to work as a scientist in the 
Department of Metabolic Diseases of the Medical Policlinic 
 
Anna Henger, Anissa Boucherot and Sandra Irrgang for expert assistance with 
real-time RT-PCR and especially for being very good friends 
 
Susanne Hillebrand, Brigitte Reinhardt and Hanna Bridell for collaboration to this 
project 
 
All my friends from Germany, USA and Romania for the good and optimistic 
thoughts during the difficult periods of time  
 
My parents, Florica and Ion, and my brother, Felix, for their unconditioned and 
endless love and encouragement.  
 
 
 
 
 
 
 
 
 
 
 
 
 
95 
CURRICULUM VITAE 
28.08.1975                        born in Bucharest, Romania 
1982 - 1990                      Primary school No.126, Bucharest, Romania 
1990 - 1995                       Pedagogical High School ″Elena Cuza″, Bucharest 
Sept. 1995 - Nov. 2000     Teacher at Elementary School, Bucharest, Romania 
1996 - 2000                       Faculty of Biology, Biochemistry section, University of  
                                          Bucharest, Romania 
Oct. 2000 - Feb. 2002       Master in Neurobiology, Faculty of Biology, University of    
                                          Bucharest, Romania    
Nov. 2000 - Jan. 2002       Research Assistant, Institute of Cellular Biology and   
                                           Pathology “Nicolae Simionescu”, Bucharest, Romania  
Feb. 2002 - Dec. 2004       PhD student, Medical Policlinic, Ludwig Maximilians   
                       University, Munich, Germany.  
96 
 
